Processing math: 79%
Review

CLEC receptors, endocytosis and calcium signaling

  • Proper immune system function is dependent on precisely evolved sensing and signal transduction events that occur at cellular and subcellular compartment boundaries. Recent immunotherapeutic efforts have generally focused on the roles that two specific protein superfamilies play in such events. This review is directed at a third superfamily, the C-type (Ca2+-dependent) lectin-type (CLEC) receptors and the nuanced, less traditionally acknowledged, yet quite important, role of endocytic-based calcium signaling. While extracellular recognition events rely heavily on the sophisticated structural diversity that lectins and glycobiology have to offer, the actual details of CLEC receptor-mediated, endocytic-based, calcium signal transduction have remained less appreciated. Because many CLEC receptor family members are emerging, not only as biomarkers for critical immune cell subpopulations, but also proving to be selective and pivotal modulators of immune function, this review seeks to promote the potential role CLEC receptor-initiated calcium signaling plays in immunotherapy. Given the importance of calcium signaling, these receptors provide a means to initiate a selective physiological response.

    Citation: Robert Cote, Laura Lynn Eggink, J. Kenneth Hoober. CLEC receptors, endocytosis and calcium signaling[J]. AIMS Allergy and Immunology, 2017, 1(4): 207-231. doi: 10.3934/Allergy.2017.4.207

    Related Papers:

    [1] Nisar Gul, Saima Noor, Abdulkafi Mohammed Saeed, Musaad S. Aldhabani, Roman Ullah . Analytical solution of the systems of nonlinear fractional partial differential equations using conformable Laplace transform iterative method. AIMS Mathematics, 2025, 10(2): 1945-1966. doi: 10.3934/math.2025091
    [2] Muhammad Akram, Ghulam Muhammad, Tofigh Allahviranloo, Ghada Ali . A solving method for two-dimensional homogeneous system of fuzzy fractional differential equations. AIMS Mathematics, 2023, 8(1): 228-263. doi: 10.3934/math.2023011
    [3] Muammer Ayata, Ozan Özkan . A new application of conformable Laplace decomposition method for fractional Newell-Whitehead-Segel equation. AIMS Mathematics, 2020, 5(6): 7402-7412. doi: 10.3934/math.2020474
    [4] Zeliha Korpinar, Mustafa Inc, Dumitru Baleanu . On the fractional model of Fokker-Planck equations with two different operator. AIMS Mathematics, 2020, 5(1): 236-248. doi: 10.3934/math.2020015
    [5] Muhammad Akram, Ghulam Muhammad, Tofigh Allahviranloo, Ghada Ali . New analysis of fuzzy fractional Langevin differential equations in Caputo's derivative sense. AIMS Mathematics, 2022, 7(10): 18467-18496. doi: 10.3934/math.20221016
    [6] Sumbal Ahsan, Rashid Nawaz, Muhammad Akbar, Saleem Abdullah, Kottakkaran Sooppy Nisar, Velusamy Vijayakumar . Numerical solution of system of fuzzy fractional order Volterra integro-differential equation using optimal homotopy asymptotic method. AIMS Mathematics, 2022, 7(7): 13169-13191. doi: 10.3934/math.2022726
    [7] M. Mossa Al-Sawalha, Khalil Hadi Hakami, Mohammad Alqudah, Qasem M. Tawhari, Hussain Gissy . Novel Laplace-integrated least square methods for solving the fractional nonlinear damped Burgers' equation. AIMS Mathematics, 2025, 10(3): 7099-7126. doi: 10.3934/math.2025324
    [8] Emad Salah, Ahmad Qazza, Rania Saadeh, Ahmad El-Ajou . A hybrid analytical technique for solving multi-dimensional time-fractional Navier-Stokes system. AIMS Mathematics, 2023, 8(1): 1713-1736. doi: 10.3934/math.2023088
    [9] Mahmoud Abul-Ez, Mohra Zayed, Ali Youssef . Further study on the conformable fractional Gauss hypergeometric function. AIMS Mathematics, 2021, 6(9): 10130-10163. doi: 10.3934/math.2021588
    [10] Naveed Iqbal, Imran Khan, Rasool Shah, Kamsing Nonlaopon . The fuzzy fractional acoustic waves model in terms of the Caputo-Fabrizio operator. AIMS Mathematics, 2023, 8(1): 1770-1783. doi: 10.3934/math.2023091
  • Proper immune system function is dependent on precisely evolved sensing and signal transduction events that occur at cellular and subcellular compartment boundaries. Recent immunotherapeutic efforts have generally focused on the roles that two specific protein superfamilies play in such events. This review is directed at a third superfamily, the C-type (Ca2+-dependent) lectin-type (CLEC) receptors and the nuanced, less traditionally acknowledged, yet quite important, role of endocytic-based calcium signaling. While extracellular recognition events rely heavily on the sophisticated structural diversity that lectins and glycobiology have to offer, the actual details of CLEC receptor-mediated, endocytic-based, calcium signal transduction have remained less appreciated. Because many CLEC receptor family members are emerging, not only as biomarkers for critical immune cell subpopulations, but also proving to be selective and pivotal modulators of immune function, this review seeks to promote the potential role CLEC receptor-initiated calcium signaling plays in immunotherapy. Given the importance of calcium signaling, these receptors provide a means to initiate a selective physiological response.


    Fuzzy set theory plays a crucial role in exploring and analyzing a wide range of real-world problems, including quantum mechanics, astronomy, electronic mechanisms, quantum optics, artificial intelligence, population dynamics models, finance, technology, pattern recognition, economics, biology, and medicine [1,2,3,4,5]. Moreover, the application of fuzzy differential equations enables the modeling and solution of various mathematical problems in these fields, making them indispensable tools in applied mathematics [6,7,8,9,10].

    Fuzzy set theory was initially established by Zadeh [1]. Subsequently, Dubois and Prade [11] introduced the concepts of fuzzy differential and differential integration for fuzzy valued functions. Furthermore, various researchers have made significant contributions to the field. Guo et al. [4] developed fuzzy population models, Agarwal et al. [12] introduced fuzzy fractional differential equations (FFDEs), and Fard and Salehi [13] along with Soolaki et al. [14] discussed fuzzy fractional variational problems using Caputo and combined Caputo differentiability, respectively. Zhang et al. [15] established generalized necessary and sufficient optimality conditions for fuzzy fractional problems based on the Atangana-Baleanu fractional derivative (FD) and generalized Hukuhara difference. Das and Roy [16] proposed a novel numerical method employing the Adomian decomposition method, specifically in the Riemann-Liouville sense, to solve FFDEs. Salahshour et al. [17] tackled FFDEs through fuzzy Laplace transform. Additionally, Bede and Gal [18] introduced the concept of strongly generalized differentiability for fuzzy valued functions. Hasan et al. [10] focused on the analytical and numerical solutions of fractional fuzzy hybrid systems in Hilbert space, with a specific emphasis on control using the Atangana-Baleanu Caputo FD. Finally, Behzadi et al. [19] applied the fuzzy Picard method to solve fuzzy quadratic Riccati and fuzzy Painlevé equations.

    In 2014, the conformable FD was introduced by Khalil et al. [20]. This innovative definition of FD relies on the limit concept, similar to the classical derivative. The key advantage of the conformable FD is its ease of computation compared to previous fractional definitions like Caputo Fabrizio, Atangana-Baleanu, Riemann-Liouville, and the Caputo definitions [21,22,23,24,25]. Notably, the conformable FD satisfies all the fundamental concepts of the classical derivative, while other fractional derivative definitions may fall short in this aspect.

    Moreover, the conformable FD offers the ability to compute for non-differentiable functions and provides efficient solutions for FFDEs and systems. It also brings modifications to significant transforms such as Laplace, Sumudu, and Nature transforms, making them effective tools for solving singular FFDEs [26]. Building upon the conformable FD, Abdeljawad [27] further developed the concept and introduced the conformable Laplace transform as a generalization of the Laplace transform in 2015.

    In 2020, Abu Arqub and Al-Smadi [28] proposed the fuzzy conformable FD and integral. These concepts were employed to derive solutions for specific FFDEs involving strongly generalized differentiability. Recently, the fuzzy conformable Laplace (FCL) transform has been investigated as an analytic method for solving FFDEs by authors such as Harir et al. [29] and Sadabadi et al. [30].

    In recent studies by Bataineh et al. [31], and Al-Zhour et al. [32], the residual power series method was utilized to obtain approximate solutions for FFDEs in the conformable sense. The method was applied under the assumption of strongly generalized differentiability. These equations have a general form as following initial value problem (IVP):

    Pβψ(t)=Z(t,ψ(t)), atb, β(0,1], (1.1)

    with the fuzzy initial condition (F-IC):

    ψ(0)=τ, (1.2)

    where Pβ represents the fuzzy conformable FD of order β, Z: [a,b]×FF is a continuous analytical fuzzy valued function, ψ is an analytical fuzzy valued function, τF, where F is the set containing all fuzzy numbers.

    There are three primary approaches for solving FFDEs in a conformable sense with fuzzy-initial conditions (F-ICs). The first approach involves dealing with the case where the initial value is a fuzzy number. In this scenario, the solution becomes a fuzzy function, necessitating the consideration of fuzzy derivatives. To address this problem, the use of strongly generalized differentiability is required. The second approach entails transforming the FFDEs into crisp equations, represented as a set of differential inclusions. However, a major drawback of using differential inclusions is the absence of a fuzzification of the differential operator. Consequently, the solution is not inherently a fuzzy-valued function. The last approach revolves around the crisp equation and the initial fuzzy values, which are in the solution. The weakness lies in the need to rewrite the solution in the fuzzy setting, which makes the solution techniques less user-friendly and more restricted, requiring numerous computational steps. To overcome this, we can substitute the crisp equation and the initial fuzzy values with real constants and arithmetic operations, treating them as operations on fuzzy numbers in the final solution. The latest approach, which focuses on exploring the fuzzy set of real-valued functions rather than fuzzy-valued functions, exemplifies the fulfillment of the aforementioned constraints.

    In 2020, a new method called the Laplace-residual power series method (L-RPSM) was proposed and developed by Eriqat et al. [33]. This analytical numerical method aimed to enhance the simplicity and efficiency of the residual power series method for solving fractional differential equations (FDEs) in various fields of engineering and science. The L-RPSM demonstrated improved effectiveness in generating both exact and approximate solutions for different problems, including linear and nonlinear neutral pantograph FDEs [33], nonlinear bacteria growth model [34], nonlinear water wave FDEs [35], higher-order FDEs [36], a class of hyperbolic system of fractional FDEs [37], reaction-diffusion model [38], nonlinear time-dispersive FDEs [39], and nonlinear fisher FDEs [40]. Additionally, L-RPSM was employed by Oqielat et al. [41,42] for solving fuzzy quadratic Riccati equations and fuzzy fractional population dynamics model and others [43,44,45,46,47,48,49,50,51].

    The main goal of this paper is to find the exact solutions for FFDEs in the conformable sense under strongly generalized differentiability, as shown in (1.1) and (1.2). To achieve this objective, we have developed an efficient analytical algorithm based on the L-RPSM. Our algorithm involves applying the FCL transform to simplify the targeted equation. Then, we construct a new expansion using novel perspectives and theories to assume a series solution for the target equation in the FCL space. Subsequently, we utilize important facts related to the FCL residual functions to determine the coefficients of the assumed series solutions. Finally, we apply the inverse FCL transform to the series solutions in FCL space. This process allows us to obtain the exact solution in the form of a fuzzy convergent conformable fractional series, which represents the precise solution to the target equation in the original space.

    The remaining sections of the paper are organized as follows: Firstly, we provide a brief retrieval of primary definitions and theorems related to fuzzy conformable fractional calculus in Section 2. Following that, in Section 3, we present a new expansion for constructing solutions to FFDEs in the conformable sense, along with an explanation of the definitions and theories associated with FCL transform theory. In Section 4, we extend the efficient analytic fractional conformable L-RPSM algorithm to effectively solve FFDEs in the conformable sense. In Section 5, we present specific numerical examples. Finally, in Section 6, we summarize the key findings and offer concluding remarks.

    In this section, we present the basic definitions and initial findings that are necessary for comprehending the theory of sufficient fuzzy analysis. This understanding will allow us to explore the solutions for specific categories of FFDEs. Throughout this article, we will utilize the notation F to represent the set encompassing all fuzzy numbers.

    Definition 1. ([20]) The operator Pβ, which represents the β-th conformable FD of a function φ:[η,)R starting from η, is expressed as follows:

    Pβφ(t)=limϵ0φ(m1)(t+ϵ(tη)mβ)φ(m1)(t)ϵ,β(m1,m], t>η, (2.1)

    and Pβφ(η)=limtη+Pβφ(t) provided that limtη+Pβφ(t) exists and φ(t) is (m1)-differentiable in some (0,η).

    Definition 2. ([9]) A fuzzy set ψ is a set that maps from the real numbers () to the range of [0, 1], and is defined as a fuzzy number if

    ψ is normal, i.e., there is at least one point ξ such that ψ(t)=1.

    ψ is convex, i.e., for each ξ, η, and 0γ1, we have ψ(γξ+(1γ)η) min (ψ(ξ),ψ(η)).

    ψ is upper semi-continuous, i.e., limtξ ψ(t)ψ(ξ),ξ.

    [ψ]0=¯{ξ:ψ(ξ)>0} is compact set.

    Theorem 1. ([5]) Assume ψ_,¯ψ:[0,1] hold the following conditions:

    1) ψ_ is a bounded monotonic non-decreasing function.

    2) ¯ψ is a bounded monotonic non-increasing function.

    3) ψ_(1)¯ψ(1).

    4) For each i(0,1], limiψ_()=ψ_(i) and limi¯ψ()=¯ψ(i).

    5) lim0+ψ_()=ψ_(0) and lim0+¯ψ()=¯ψ(0).

    Then, ψ:[0,1] defined by ψ(t)=sup{|ψ_()t¯ψ()} is a fuzzy number with -level set: [ψ_,¯ψ]. Furthermore, if ψ:[0,1] is a fuzzy number with -level set [ψ_,¯ψ], then the functions ψ_ and ¯ψ fulfill the conditions (i)–(v) mentioned above. Therefore, it is possible to represent the arbitrary fuzzy number ψ as a pair of ordered functions (ψ_,¯ψ).

    Definition 3. ([52]) For D:F×F+{0}, assume ψ=(ψ_,¯ψ) and φ=(φ_,¯φ) an arbitrary fuzzy numbers, then the mapping D(ψ,φ) can be defined as D(ψ,φ)=sup01DH{[ψ],[φ]}, where DH is the Hausdroff metric:

    DH{[ψ],[φ]}=max{|ψ_φ_|,|¯ψ¯φ|}. (2.2)

    The Zadeh's Extension Principle is employed to define addition and scalar multiplication on D, resulting in a reduction of these operations to interval operations

    [ψ+φ]=[ψ]+[φ], [γψ]=γ[ψ], ψ,φF, γ/{0},[0,1]. (2.3)

    We consider the differentiability of fuzzy-valued functions in the sense of H-difference, by using the following difference.

    Definition 4. ([52]) Let ψ,φF and [0,1], if the exists ϑF such that ψ=φ+ϑ, then ϑ is called H-difference of ψ and φ, denoted by ψφ, and defined as follows:

    ψφ=[ψ][φ]. (2.4)

    Definition 5. ([28]) The fuzzy conformable FD of order β>0 for fuzzy function ψ: (a,b)F is denoted by Pβ and defined as:

    Pβψ(t)=limζ0+ψ(t+ζt1β)ψ(t)ζ=limζ0+ψ(t)ψ(tζt1β)ζ,β(0,1]. (2.5)

    Definition 6. ([10,28]) For t0[a,b], a>0, and β>0, we say that ψ: [a,b]F is strongly-generalized βth-fuzzy conformable differentiable (βth-FCD) at t0 if there exists an element Pβψ(ι)F such that either:

    1) The H-differences

    ψ(t0+ζt1β0)ψ(t0),ψ(t0)ψ(t0ζt1β0) (2.6)

    exist for each sufficiently small ζ>0, and

    limζ0+ψ(t0+ζt1β0)ψ(t0)ζ=limζ0+ψ(t0)ψ(t0ζt1β0)ζ=Pβψ(t0).

    2) The H-differences

    ψ(t0)ψ(t0+ζt1β0),ψ(t0ζt1β0)ψ(t0), (2.7)

    exist for each sufficiently small ζ>0, and

    limζ0+ψ(t0)ψ(t0+ζt1β0)ζ=limζ0+ψ(t0ζt1β0)ψ(t0)ζ=Pβψ(t0).

    It is worth mentioning here that the limits are taken in the metric space (F,D).

    Remark 1. If ψ satisfies the conditions of Definition 6-1), being fuzzy differentiable for any point t(a,b), then ψ can be considered a (1;β)-FCD on the interval [a,b] with its derivative given by Pβ1ψ(t). Similarly, if ψ satisfies the conditions of Definition 6-2), being fuzzy differentiable for any point t(a,b), then ψ can be regarded as a (2;β)-FCD on the interval [a,b], and its derivative is Pβ2ψ(t).

    Theorem 2. ([10]) Assume that ψ:[a,b]F is a fuzzy function satisfies the following conditions:

    1) For each t[a,b], there exists λ>0 such that the H-differences: ψ(t+ζt1β)ψ(t) and ψ(t)ψ(tζt1β) exists for all ζ[0,λ).

    2) For each t[a,b] and h>0 there exists a constant l>0 such that DH(ψ(t+ζt1β)ψ(t)ζ,Pβψ(t))<h, and DH(ψ(t)ψ(tζt1β)ζ,Pβψ(t))<h, for all ζ[0,l). Then, the set of functions [ψ(t)] is βth-FCD and its derivative is [Pβψ(t)]=[Pβψ_(t),Pβ¯ψ(t)], where [ψ(t)]=[ψ_(t),¯ψ(t)] for each [0,1].

    Theorem 3. ([10,28]) Assume that ψ:[a,b]F is a fuzzy function. Let [ψ(t)]=[ψ_(t),¯ψ(t)] for each [0,1]. Then,

    1) If ψ is (1;β)-FCD, then ψ_ and ¯ψ are βth-FCD functions on [a,b] and [Pβψ(t)]=[Pβψ_(t),Pβ¯ψ(t)].

    2) If ψ is (2;β)-FCD, then ψ_ and ¯ψ are βth-FCD functions on [a,b] and [Pβψ(t)]=[Pβ¯ψ(t),Pβψ_(t)].

    In this section, we review and construct the definitions and theories related to FCL transform that will be used to construct our approach for solving FFDEs in the conformable sense.

    Definition 7. ([29,30]) Let β(0,1] and [ψ(t)] be a continuous fuzzy value function for [0,1]. If the function estββ[ψ(t)]tβ1 is integrable on [0,), then the FCL transform of order β starting from zero of [ψ(t)] is defined as:

    Lβ[[ψ(t)]]=0estββ[ψ(t)]tβ1dt, s>0.

    Moreover, we have

    0estββ[ψ(t)]tβ1dt=[0estββψ_(t)tβ1dt,0estββ¯ψ(t)tβ1dt].

    In parametric form, we get

    Lβ[[ψ(t)]]=[Lβ[ψ_(t)],Lβ[¯ψ(t)]],

    where,

    Lβ[ψ_(t)]=0estββψ_(t)tβ1dt,
    Lβ[¯ψ(t)]=0estββ¯ψ(t)tβ1dt.

    Theorem 4. ([29]) Let β(0,1] and ψ:[a,b]F be a continuous fuzzy function for [0,1] such that Lβ[[ψ(t)]]=[Ψ(s)] exists. Then, the following equation holds:

    [Ψ(s)]=L[[ψ((βt)1β)]],

    where L[[g(t)]]=0est[g(t)]dt.

    Lemma 1. Let β(0,1], ψ:[a,b]F and φ:[a,b]F be continuous fuzzy functions for [0,1] and of exponential order ȷ and ϕ respectively. Suppose Lβ[[ψ(t)]]=[Ψ(s)] and Lβ[[φ(t)]]=[Φ(s)] are exist, where s>0 and γ and μ are constants. Then, the following properties hold:

    1) Lβ[γ[ψ(t)]+μ[φ(t)]]=γ[Ψ(s)]+μ[Φ(s)].

    2) Lβ[γ]=γs.

    3) Lβ[tγ]=βγβΓ(1+γβ)s1+γβ.

    4) Lβ[sin(γtββ)]=γγ2+s2.

    5) Lβ[cos(γtββ)]=sγ2+s2.

    6) Lβ[tnβ[ψ(t)]]=(β)ndndsn[Ψ(s)].

    Proof. Part (1)–(5) have been proven in [27,29]. Now, to prove part (6), consider the following identity

    (β)dds[Ψ(s)]=(β)dds[Ψ_(s),¯Ψ(s)]=[(β)ddsΨ_(s),(β)dds¯Ψ(s)]=(β)dds0estββ[ψ(t)]tβ1dt.

    Therefore, we have:

    (β)ddsΨ_(s)=(β)dds0estββψ_(t)tβ1dt=(β)0dds(estββ)ψ_(t)tβ1dt=0estββtβψ_(t)tβ1dt=Lβ[tβψ_(t)],
    (β)dds¯Ψ(s)=(β)dds0estββ¯ψ(t)tβ1dt=(β)0dds(estββ)¯ψ(t)tβ1dt=0estββtβ¯ψ(t)tβ1dt=Lβ[tβ¯ψ(t)].

    Thus, we obtain:

    (β)dds[Ψ(s)]=[Lβ[tβψ_(t)],Lβ[tβ¯ψ(t)]]=Lβ[tβ[ψ(t)]].

    The general result now follows by induction on n. Hence, if ψ is (1;β)-FCD, the proof of the fact is concluded. Similarly, we can employ a similar approach to establish the result when ψ is (2;β)-FCD.

    Theorem 5. ([29,30]) Assume that β(0,1] and ψ:[a,b]F is a fuzzy function. Let [ψ(t)]=[ψ_(t),¯ψ(t)] for each [0,1] and Lβ[[ψ(t)]]=[Ψ(s)]=[Ψ_(s),¯Ψ(s)] exists. Then,

    1) If ψ is (1;β)-FCD, then

    Lβ[[Pβψ(t)]]=s[Ψ(s)][ψ(0)].

    In parametric form, we get

    Lβ[[Pβψ(t)]]=[Lβ[Pβψ_(t)],Lβ[Pβ¯ψ(t)]],

    where

    Lβ[Pβψ_(t)]=sΨ_(s)ψ_(0),
    Lβ[Pβ¯ψ(t)]=s¯Ψ(s)¯ψ(0).

    2) If ψ is (2;β)-FCD, then

    Lβ[[Pβψ(t)]]=([ψ(0)])((s)[Ψ(s)]).

    In parametric form, we get

    Lβ[[Pβψ(t)]]=[Lβ[Pβ¯ψ(t)],Lβ[Pβψ_(t)]],

    where

    Lβ[Pβψ_(t)]=sΨ_(s)ψ_(0),
    Lβ[Pβ¯ψ(t)]=s¯Ψ(s)¯ψ(0).

    Theorem 6. Let β(0,1] and ψ:[a,b]F be a continuous fuzzy function for [0,1] such that Lβ[[ψ(t)]]=[Ψ(s)] exists. Then

    1) If ψ is (1;β)-FCD, then

    Lβ[[Pnβψ(t)]]=sn[Ψ(s)]n1j=0snj1[Pjβψ(0)].

    In parametric form, we get

    Lβ[[Pnβψ(t)]]=[Lβ[Pnβψ_(t)],Lβ[Pnβ¯ψ(t)]],

    where

    Lβ[Pnβψ_(t)]=snΨ_(s)n1j=0snj1Pjβψ_(0),
    Lβ[Pnβ¯ψ(t)]=sn¯Ψ(s)n1j=0snj1Pjβ¯ψ(0).

    2) If ψ is (2;β)-FCD, then

    Lβ[[Pnβψ(t)]]=(n1j=0snj1[Pjβψ(0)])((sn)[Ψ(s)]).

    In parametric form, we get

    Lβ[[Pβψ(t)]]=[Lβ[Pβ¯ψ(t)],Lβ[Pβψ_(t)]],

    where

    Lβ[Pnβψ_(t)]=snΨ_(s)n1j=0snj1Pjβψ_(0),
    Lβ[Pnβ¯ψ(t)]=sn¯Ψ(s)n1j=0snj1Pjβ¯ψ(0),

    where Pnβ means apply conformable FD, Pβ, n-times.

    Proof. Assume that ψ(t) is (1;β)-FCD for [0,1]. In parametric form for n=2, we get Lβ[[P2βψ(t)]]=[Lβ[P2βψ_(t)],Lβ[P2β¯ψ(t)]].

    Using Theorem 5, we have:

    Lβ[P2βψ_(t)]=Lβ[PβPβψ_(t)]=sLβ[Pβψ_(t)]Pβψ_(0)=s[sΨ_(s)ψ_(0)]Pβψ_(0)=s2Ψ_(s)sψ_(0)Pβψ_(0),
    Lβ[P2β¯ψ(t)]=Lβ[PβPβ¯ψ(t)]=sLβ[Pβ¯ψ(t)]Pβ¯ψ(0)=s[s¯Ψ(s)¯ψ(0)]Pβ¯ψ(0)=s2¯Ψ(s)s¯ψ(0)Pβ¯ψ(0).

    Therefore, for n=1,2 the formula is true. Using the induction, suppose that the formula is true for n=m as

    Lβ[[Pmβψ(t)]]=sm[Ψ(s)]m1j=0smj1[Pjβψ(0)].

    To complete the proof, we have prove it true for n=m+1. In parametric form for m+1, we get Lβ[[P(m+1)βψ(t)]]=[Lβ[P(m+1)βψ_(t)],Lβ[P(m+1)β¯ψ(t)]]. Hence,

    Lβ[P(m+1)βψ_(t)]=Lβ[PβPmβψ_(t)]=sLβ[Pmβψ_(t)]Pmβψ_(0)=s[smΨ_(s)m1j=0smj1Pjβψ_(0)]Pmβψ_(0)=sm+1Ψ_(s)m1j=0smjPjβψ_(0)Pmβψ_(0)=sm+1Ψ_(s)mj=0smjPjβψ_(0),
    Lβ[P(m+1)β¯ψ(t)]=Lβ[PβPmβ¯ψ(t)]=sLβ[Pmβ¯ψ(t)]Pmβ¯ψ(0)=s[sm¯Ψ(s)m1j=0smj1Pjβ¯ψ(0)]Pmβ¯ψ(0)=sm+1¯Ψ(s)m1j=0smjPjβ¯ψ(0)Pmβ¯ψ(0)=sm+1¯Ψ(s)mj=0smjPjβ¯ψ(0).

    Thus, the formula for m+1 as below is true

    Lβ[[P(m+1)βψ(t)]]=sm+1[Ψ(s)]mj=0smj[Pjβψ(0)].

    The part (2) of the theorem can be proved in the same manner.

    Theorem 7. Let β(0,1] and ψ:[a,b]F be a continuous fuzzy function for [0,1]. If Lβ[[ψ(t)]]=[Ψ(s)] exists, and s>0. Then, the initial value theorem for FCL transform is given by

    limss[Ψ(s)]=[ψ(0)].

    Proof. We know that Lβ[[Pβψ(t)]]=[Lβ[Pβψ_(t)],Lβ[Pβ¯ψ(t)]]. Now, from the definition of FCL transform, we have,

    [Lβ[Pβψ_(t)],Lβ[Pβ¯ψ(t)]]=0estββ[Pβψ(t)]tβ1dt.

    According to Theorem 5, we have

    Lβ[Pβψ_(t)]=0estββPβψ_(t)tβ1dt=sΨ_(s)ψ_(0),Lβ[Pβ¯ψ(t)]=0estββPβ¯ψ(t)tβ1dt=s¯Ψ(s)¯ψ(0). (3.1)

    Now, taking limit as s for the expansions in Eq (3.1), we have,

    lims[0estββPβψ_(t)tβ1dt]=lims[sΨ_(s)ψ_(0)],lims[0estββPβ¯ψ(t)tβ1dt]=lims[s¯Ψ(s)¯ψ(0)]. (3.2)

    After simplify Eq (3.2), we get

    0=lims[sΨ_(s)ψ_(0)],0=lims[s¯Ψ(s)¯ψ(0)]. (3.3)

    Therefore, we have

    limssΨ_(s)=ψ_(0),limss¯Ψ(s)=¯ψ(0). (3.4)

    Therefore, the proof of the fact limss[Ψ(s)]=[ψ(0)] is complete in case ψ is (1;β)-FCD. We can use the same manner to prove it in case ψ is (2;β)-FCD.

    Definition 8. ([53]) We can define a fractional power series around t0 as the series that can be represented by the following expression:

    m=0m(tt0)mβ=0+1(tt0)β+2(tt0)2β+, 0n1<βn, tt0.

    Theorem 8. ([31]) For [0,1], let ψ_(t), and ¯ψ(t) have the following fractional expantions about t=0,

    ψ_(t)=m=0mtmβ,¯ψ(t)=m=0mtmβ, (3.5)

    where β(0,1] and t[0,R). If Pβψ_(t), and Pβ¯ψ(t) are two continuous on [0,R), then the value of the unknown coefficients m and m for m=0,1,2,, are in the forms

    m=Pmβψ_(0)βmm!,m=Pmβ¯ψ(0)βmm!, (3.6)

    where Pmβ=Pβ.PβPβ (repeated m times).

    Theorem 9. For [0,1], assume that Ψ_(s)=Lβ[ψ_(t)] and ¯Ψ(s)=Lβ[¯ψ(t)] exist and have the following expansions:

    Ψ_(s)=m=0msm+1, s>0,¯Ψ(s)=m=0msm+1, s>0. (3.7)

    Then the values of unknown coefficients m and m are expressed as m=(Pmβψ_)(0) and m=(Pmβ¯ψ)(0), where Pβψ_(t), and Pβ¯ψ(t) are two continuous functions defined on the interval [0,R), where β(0,1]. The notation Pmβ=PβPβPβ denotes the composition of the conformable FD Pβ repeated m times.

    Proof. Let us consider that Ψ_(s) and ¯Ψ(s) can be expressed using the expansions given in Eq (3.7). It is important to note that if we multiply Eq (3.7) by s and take the limit as s approaches infinity, all terms in the expansions, except the first term, become negligible. Therefore, according to Theorem 7, we can deduce that 0=limssΨ_(s)=ψ_(0) and 0=limss¯Ψ(s)=¯ψ(0). As a result, the expressions presented in Eq (3.7) can be simplified as follows:

    Ψ_(s)=ψ_(0)s+m=1msm+1, s>0,¯Ψ(s)=¯ψ(0)s+m=1msm+1, s>0. (3.8)

    Furthermore, considering other aspects, when we multiply Eq (3.8) by s2, we obtain the following expansions for 1 and 1:

    1=s2Ψ_(s)sψ_(0)m=2msm1,1=s2¯Ψ(s)s¯ψ(0)m=2msm1. (3.9)

    By taking the limit as s approaches infinity for the expressions in Eq (3.9), we obtain:

    1=lims(s2Ψ_(s)sψ_(0))=limss(sΨ_(s)ψ_(0))=limss(Lβ[Pβψ_(t)])=(Pβψ_)(0),1=lims(s2¯Ψ(s)s¯ψ(0))=limss(s¯Ψ(s)¯ψ(0))=limss(Lβ[Pβ¯ψ(t)])=(Pβ¯ψ)(0). (3.10)

    When we multiply the expressions in Eq (3.8) by s3 and take the limit as s approaches infinity, we obtain:

    2=lims(s3Ψ_(s)s2ψ_(0)s(Pβψ_)(0))=limss(s2Ψ_(s)sψ_(0)(Pβψ_)(0))=limss(Lβ[P2βψ_(t)])=(P2βψ_)(0),2=lims(s3¯Ψ(s)s2¯ψ(0)s(Pβ¯ψ)(0))=limss(s2¯Ψ(s)s¯ψ(0)(Pβ¯ψ)(0))=limss(Lβ[P2β¯ψ(t)])=(P2β¯ψ)(0). (3.11)

    By observing the patterns and continuing to multiply the expressions in Eq (3.8) by sm+1, and computing the limit of the expansions of m and m as s tends to infinity, we can derive the general formulas as follows: m=(Pmβψ_)(0) and m=(Pmβ¯ψ)(0), where m=0,1,2,. This establishes the proof of Theorem 9.

    Remark 2. The form of the inverse FCL transform for the expansions stated in Eq (3.7) as presented in Theorem 9 is given by:

    ψ_(t)=m=0Pmβψ_(0)βmm!tmβ,¯ψ(t)=m=0Pmβ¯ψ(0)βmm!tmβ,

    which is corresponding to the fractional power series in Eq (3.5) stated in Theorem 8.

    Theorem 10. Let us assume that Ψ_(s)=Lβ[ψ_(t)] and ¯Ψ(s)=Lβ[¯ψ(t)] exist for [0,1]. If we have |sLβ[P(m+1)βψ_(t)]|M and |sLβ[P(m+1)β¯ψ(t)]|N, where s, M, and N are positive numbers, then the remaining terms Rm_(s) and ¯Rm(s) of the expansions in Eq (3.7) respectively satisfy the following inequalities:

    |Rm_(s)|Msm+2, s>0,|¯Rm(s)|Nsm+2, s>0. (3.12)

    Proof. Let's begin by assuming that Pjβψ_(t) and Pjβ¯ψ(t) are defined as s>0 for j=0,1,2,,m+1. Additionally, given the conditions, let's assume that:

    |sLβ[P(m+1)βψ_(t)]|M,|sLβ[P(m+1)β¯ψ(t)]|N. (3.13)

    The expressions for the remainders Rm_(s) and ¯Rm(s) of the expansions in Eq (3.7) are given by:

    Rm_(s)=Ψ_(s)mj=0Pjβψ_(0)sj+1,¯Rm(s)=¯Ψ(s)mj=0Pjβ¯ψ(0)sj+1. (3.14)

    By considering the definition of the remainders, we can derive the following:

    sm+2Rm_(s)=sm+2Ψ_(s)mj=0sm+1jPjβψ_(0)=s(sm+1Ψ_(s)mj=0smjPjβψ_(0))=sLβ[P(m+1)βψ_(t)],sm+2¯Rm(s)=sm+2¯Ψ(s)mj=0sm+1jPjβ¯ψ(0)=s(sm+1¯Ψ(s)mj=0smjPjβ¯ψ(0))=sLβ[P(m+1)β¯ψ(t)]. (3.15)

    From Eqs (3.13) and (3.15), we can observe that |sm+2Rm_(s)|M and |sm+2¯Rm(s)|N. Therefore, we have:

    Msm+2Rm_(s)M,Nsm+2¯Rm(s)N. (3.16)

    By rearranging Eq (3.16), we can deduce the following inequalities: |Rm_(s)|Msm+2 and |¯Rm(s)|Nsm+2. These inequalities provide the necessary bounds and conclude the proof.

    In this section, we utilize the L-RPSM to generate analytical fuzzy numerical solutions for the IVPs (1.1) and (1.2), where belongs to the interval [0,1]. Our approach involves transforming the IVPs (1.1) and (1.2) into crisp systems of FFDEs. The nature of the crisp systems depends on the type of differentiability, characterized by ψ(t) as either (1;β)-FCD or (2;β)-FCD.

    To ensure clarity and without sacrificing generality, we focus solely on constructing the L-RPSM solution for (1;β)-FCD. However, using the same methodology, we can also construct the L-RPSM solution for (2;β)-FCD.

    Now, let's assume that ψ(t) represents (1;β)-FCD for [0,1]. Accordingly, the IVPs (1.1) and (1.2) can be reformulated as the following FFDEs:

    Pβψ_(t)=Z_(ψ_(t),¯ψ(t)),Pβ¯ψ(t)=¯Z(ψ_(t),¯ψ(t)), (4.1)

    with the F-ICs:

    ψ_(0)=ω_,¯ψ(0)=¯ω, (4.2)

    where t[0,b] and β(0,1].

    Utilize the L-RPSM, we first employ the FCL transform for the expansions in Eq (4.1) as follows:

    Lβ[Pβψ_(t)]=Lβ[Z_(ψ_(t),¯ψ(t))],Lβ[Pβ¯ψ(t)]=Lβ[¯Z(ψ_(t),¯ψ(t))]. (4.3)

    Based on Theorem 5, we can express the expansions presented in Eq (4.3) in the following manner:

    sΨ_(s)ψ_(0)=Lβ[Z_(L1β[Ψ_(s)],L1β[¯Ψ(s)])],s¯Ψ(s)¯ψ(0)=Lβ[¯Z(L1β[Ψ_(s)],L1β[¯Ψ(s)])], (4.4)

    where Ψ_(s)=Lβ[ψ_(t)] and ¯Ψ(s)=Lβ[¯ψ(t)].

    The main idea of L-RPSM is to construct the solution for the target equation in FCL space as in Eq (4.4), and then employ inverse FCL transform for this solution to obtain the solution for the target equation in the original space. To achieve our goal, we assume that the solution for the expansions in Eq (4.4) has the following expression:

    Ψ_(s)=m=0msm+1, s>0,¯Ψ(s)=m=0msm+1, s>0.

    Furthermore, we can utilize the initial value theorem for the FCL transform, as stated in Theorem 7, to establish that 0=limssΨ_(s)=ψ_(0)=ω_ and 0=limss¯Ψ(s)=¯ψ(0)=¯ω. Consequently, we can express the L-RPSM solutions for the expansions in Eq (4.4) as follows:

    Ψ_(s)=ω_s+m=1msm+1,¯Ψ(s)=¯ωs+m=1msm+1. (4.5)

    In order to utilize the L-RPSM and determine the values of the unknown coefficients in the series presented in Eq (4.5), we define the Laplace residual function of the expansions in Eq (4.4) in the following manner:

    LRes_(s)=Ψ_(s)s1ω_s1Lβ[Z_(L1β[Ψ_(s)],L1β[¯Ψ(s)])],¯LRes(s)=¯Ψ(s)s1¯ωs1Lβ[¯Z(L1β[Ψ_(s)],L1β[¯Ψ(s)])]. (4.6)

    Below are a few key facts regarding the FCL residual functions:

    1) LRes_(s)=0 and ¯LRes(s)=0.

    2) Since Z_ and ¯Z are analytic functions, Eq (4.6) take the following expressions:

    LRes_(s)=m=1msm+1m=0Z_m(0,1,,m,0,1,,m)sm+2=m=1mZ_m1(ı,ı)sm+1, ı{0,1,2,,m1}, s>0,¯LRes(s)=m=1msm+1m=0¯Zm(0,1,,m,0,1,,m)sm+2=m=1m¯Zm1(ı,ı)sm+1, ı{0,1,2,,m1}, s>0, (4.7)

    where Z_m and ¯Zm, m=1,2, are fuzzy operators.

    1) Since LRes_(s)=0 and ¯LRes(s)=0, s>0, we have mZ_m1(ı,ı)=0 and m¯Zm1(ı,ı)=0, for m=1,2,, and ı{0,1,2,,m1}.

    2) After a few straightforward collocation steps, we obtain the values of the coefficients m and m for m=1,2, in the following form:

    m=Z_m1(ı,ı),m=¯Zm1(ı,ı), (4.8)

    where m=1,2,, and ı{0,1,2,,m1}.

    Hence, by substituting the calculated coefficients back into Eq (4.5), we can express the exact solutions for Eq (4.4) in the FCL space as an infinite series in the following manner:

    Ψ_(s)=ω_s+Z_0(ω_,¯ω)s2+m=2Z_m1(ı,ı)sm+1,¯Ψ(s)=¯ωs+¯Z0(ω_,¯ω)s2+m=2¯Zm1(ı,ı)sm+1. (4.9)

    The final stage of the L-RPSM involves transforming the solution presented in Eq (4.9) back to the original space by applying the inverse FCL transform to the expressions in Eq (4.9). Consequently, the exact solution for the IVPs (4.1) and (4.2) can be represented as an infinite series in the following manner:

    ψ_(t)=ω_+Z_0(ω_,¯ω)βtβ+m=2Z_m1(ı,ı)βmm!tmβ,¯ψ(t)=¯ω+¯Z0(ω_,¯ω)βtβ+m=2¯Zm1(ı,ı)βmm!tmβ. (4.10)

    To provide further clarity, we have outlined the following algorithm:

    Algorithm 1. The procedure for obtaining the L-RPSM solutions for the IVPs (4.1) and (4.2) is as follows:

    Step A. Apply the FCL transform to Eq (4.1), resulting in:

    Ψ_(s)s1ω_s1Lβ[Z_(L1β[Ψ_(s)],L1β[¯Ψ(s)])]=0,¯Ψ(s)s1¯ωs1Lβ[¯Z(L1β[Ψ_(s)],L1β[¯Ψ(s)])]=0,

    where Ψ_(s)=Lβ[ψ_(t)] and ¯Ψ(s)=Lβ[¯ψ(t)].

    Step B. Express the solutions Ψ_(s) and ¯Ψ(s) of the expressions in Step A as follows:

    Ψ_(s)=ω_s+m=0msm+1,¯Ψ(s)=¯ωs+m=0msm+1.

    Step C. Define the FCL residual functions as follows:

    LRes_(s)=Ψ_(s)s1ω_s1Lβ[Z_(L1β[Ψ_(s)],L1β[¯Ψ(s)])],¯LRes(s)=¯Ψ(s)s1¯ωs1Lβ[¯Z(L1β[Ψ_(s)],L1β[¯Ψ(s)])].

    Step D. Substitute the series solution in Step B into the FCL residual functions in Step C as:

    LRes_(s)=m=1msm+1s1Lβ[Z_(L1β[m=0msm+1],L1β[m=0msm+1])],¯LRes(s)=m=1msm+1s1Lβ[¯Z(L1β[m=0msm+1],L1β[m=0msm+1])].

    Step E. Rearrange the terms of the expansions for the equations in Step D and collect it to the same power of s, resulting in:

    LRes_(s)=m=1mZ_m1(ı,ı)sm+1, ı{0,1,2,,m1}, s>0,¯LRes(s)=m=1m¯Zm1(ı,ı)sm+1, ı{0,1,2,,m1}, s>0,

    where Z_m and ¯Zm, m=1,2, are fuzzy operators.

    Step F. Utilize the facts LRes_(s)=0 and ¯LRes(s)=0 to derive the expressions for the coefficient values as follows:

    m=Z_m1(ı,ı),m=¯Zm1(ı,ı),

    where m=1,2,, and ı{0,1,2,,m1}.

    Step G. Substitute the coefficients m and m, m=1,2, into the series solutions in Step B.

    Step H. Employ the inverse FCL transform on the Ψ_(s) and ¯Ψ(s) to obtain the L-RPSM solutions ψ_(t) and ¯ψ(t) of the IVPs (4.1) and (4.2). Then, stop.

    Similarly, using the same methodology, we can construct series solutions for the crisp system of FFDEs when ψ(t) represents (2;β)-FCD.

    In this section, we address three important and interesting applications. We discuss and analyze the numerical simulations of these applications and present graphical results for various parameters. Our computational and presentation processes involve the utilization of both MATHEMATICA 11 and MAPLE 2018.

    Application 1. ([31]) Consider the following fuzzy conformable fractional IVPs

    Pβψ(t)=[+1,3]+ψ(t), 0t1, β(0,1], (5.1)

    subject to the following F-IC:

    ψ(0)=0, (5.2)

    where [0,1].

    We will now examine two specific cases for dealing with the solutions for the applications, which are as follows:

    Case 1: If ψ(t) is (1;β)-FCD, then the crisp system of the fuzzy conformable fractional IVPs (5.1) and (5.2) can be written in the following form:

    Pβψ_(t)=(+1)+ψ_(t),Pβ¯ψ(t)=(3)+¯ψ(t), (5.3)

    subject to the following F-ICs:

    ψ_(0)=0,¯ψ(0)=0. (5.4)

    Utilizing the L-RPSM, the FCL transform of the crisp system in Eq (5.3) takes the form:

    Ψ_(s)s2(+1)s1Ψ_(s)=0,¯Ψ(s)s2(3)s1¯Ψ(s)=0, (5.5)

    where Ψ_(s)=Lβ[ψ_(t)] and ¯Ψ(s)=Lβ[¯ψ(t)].

    In this orientation as well, the fuzzy series solutions of the expansions in Eq (5.5) can be written as:

    Ψ_(s)=m=1msm+1,¯Ψ(s)=m=1msm+1, (5.6)

    and the FCL residual functions of the crisp system in Eq (5.5) is represented as:

    LRes_(s)=Ψ_(s)s2(+1)s1Ψ_(s),¯LRes(s)=¯Ψ(s)s2(3)s1¯Ψ(s). (5.7)

    Substitute the expansions of series solution in Eq (5.6) into the FCL residual functions in Eq (5.7), respectively, as:

    LRes_(s)=m=1msm+1(+1)s2m=1msm+2=1(+1)s2+m=2mm1sm+1, s>0,¯LRes(s)=m=1msm+1(3)s2m=1msm+2=1(3)s2+m=2mm1sm+1, s>0. (5.8)

    Since LRes_(s)=0 and ¯LRes(s)=0, the recurrence relation which determines the values of the coefficients m and m, m=1,2, given by:

    1=(+1), m=m1, m=2,3,,1=(3), m=m1, m=2,3,. (5.9)

    Compute and substitute the values of the coefficients m and m, m=1,2, back into Eq (5.6) to have the solutions of Eq (5.5) in FCL space as following series form:

    Ψ_(s)=m=1(+1)sm+1,¯Ψ(s)=m=1(3)sm+1. (5.10)

    Employ the inverse FCL transform into the expansions in Eq (5.10) to have the exact solutions of IVPs (5.3) and (5.4) in the original space as follows:

    ψ_(t)=m=1(+1)βmm!tmβ=(+1)(etββ1),¯ψ(t)=m=1(3)βmm!tmβ=(3)(etββ1). (5.11)

    For the standard case β=1, Eq (5.11) have the following form:

    ψ_(t)=(+1)m=1tmm!=(+1)(et1),¯ψ(t)=(3)m=1tmm!=(3)(et1), (5.12)

    which are equivalent to the exact solutions [ψ(t)]=[+1,3](et1) of the IVPs (5.3) and (5.4) in ordinary derivative.

    Case 2: If ψ(t) is (2;β)-FCD, then the crisp system of the fuzzy conformable fractional IVPs (5.1) and (5.2) can be written in the following form:

    Pβψ_(t)=(3)+¯ψ(t),Pβ¯ψ(t)=(+1)+ψ_(t), (5.13)

    subject to the following F-ICs:

    ψ_(0)=0,¯ψ(0)=0. (5.14)

    The form of the crisp system in Eq (5.13) in FCL space is obtained by utilizing the FCL transform, and it can be written as:

    Ψ_(s)s2(3)s1¯Ψ(s)=0,¯Ψ(s)s2(+1)s1Ψ_(s)=0, (5.15)

    where Ψ_(s)=Lβ[ψ_(t)] and ¯Ψ(s)=Lβ[¯ψ(t)].

    Similarly, in this particular orientation, the expansions in Eq (5.15) can be expressed as fuzzy series solutions in the following manner:

    Ψ_(s)=m=1msm+1,¯Ψ(s)=m=1msm+1. (5.16)

    The representation of the FCL residual functions for the crisp system in Eq (5.15) can be given as:

    LRes_(s)=Ψ_(s)s2(3)s1¯Ψ(s),¯LRes(s)=¯Ψ(s)s2(+1)s1Ψ_(s). (5.17)

    By substituting the series solution expansions from Eq (5.16) into the FCL residual functions stated in Eq (5.17), we obtain the following expression:

    LRes_(s)=m=1msm+1(3)s2m=1msm+2=1(3)s2+m=2mm1sm+1, s>0,¯LRes(s)=m=1msm+1(+1)s2m=1msm+2=1(+1)s2+m=2mm1sm+1, s>0. (5.18)

    The recurrence relation that governs the values of the coefficients m and m is established based on the facts LRes_(s)=0 and ¯LRes(s)=0. It can be expressed as follows:

    1=(3), m=m1, m=2,3,,1=(+1), m=m1, m=2,3,. (5.19)

    To obtain the solutions of Eq (5.15) in FCL space, we compute and substitute the values of the coefficients m and m, where m=1,2,, back into Eq (5.16). This results in the solutions taking the following series form:

    Ψ_(s)=m=1(3)s2m+m=1(+1)s2m+1,¯Ψ(s)=m=1(+1)s2m+m=1(3)s2m+1. (5.20)

    By applying the inverse FCL transform to the expansions presented in Eq (5.20), we can obtain the exact solutions of IVPs (5.13) and (5.14) in the original space. The solutions are given as follows:

    ψ_(t)=m=1(3)β(2m1)(2m1)!t(2m1)β+m=1(+1)β2m(2m)!t2mβ=2(etββ1)+(1)(1etββ),¯ψ(t)=m=1(+1)β(2m1)(2m1)!t(2m1)β+m=1(3)β2m(2m)!t2mβ=2(etββ1)+(1)(1etββ). (5.21)

    In the case where β=1, Eq (5.21) takes on the following form:

    ψ_(t)=(3)m=1t2m1(2m1)!+(+1)m=1t2m(2m)!=2(et1)+(1)(1et),¯ψ(t)=(+1)m=1t2m1(2m1)!+(3)m=1t2m(2m)!=2(et1)+(1)(1et), (5.22)

    which are equivalent to the exact solutions [ψ(t)]=2(et1)+[1,1](1et) of the target problems in ordinary derivative.

    Figure 1 presents the surface graphs of the solutions of Application 1 for both cases at different values of β. Figure 2 provide the 2D graphs of the solutions of Application 1 at β=1 for different values of . Numerical simulation of the solutions is performed of Application 1 for both cases at different values of and β with some selected grid points on the interval [0,1] as shown in Table 1.

    Figure 1.  The surface graphs of the solutions for Application 1: (a) [ψ(t)] at β=0.5, case 1, (b) [ψ(t)] at β=0.5, case 2, (c) [ψ(t)] at β=1, case 1, (d) [ψ(t)] at β=1, case 2.
    Figure 2.  The 2D graphs of the solutions for Application 1 at β=1: (a) [ψ(t)], case 1, (b) [ψ(t)], case 2.
    Table 1.  Numerical results of [ψ_(t),¯ψ(t)] for Application 1.
    [ψ_(t),¯ψ(t)]; ψ(t) is (1;β)-CFD [ψ_(t),¯ψ(t)]; ψ(t) is (2;β)-CFD
    t β=0.75 β=1 β=0.75 β=1
    0.2 [0.61247, 1.34743] [0.27675, 0.60886] [1.22659, 0.73332] [0.57876, 0.30685]
    0.4 [1.19434, 2.62755] [0.61478, 1.35252] [2.27740, 1.54448] [1.23091, 0.73639]
    0.25 0.6 [1.85222, 4.07489] [1.02765, 2.26083] [3.41135, 2.51576] [1.98263, 1.30585]
    0.8 [2.61131, 5.74488] [1.53193, 3.37024] [4.68530, 3.67089] [2.86409, 2.03808]
    1.0 [3.49208, 7.68259] [2.14785, 4.72528] [6.13964, 5.03503] [3.91065, 2.96247]
    0.2 [0.85746, 1.10244] [0.38746, 0.49816] [1.06216, 0.89774] [0.48812, 0.39749]
    0.4 [1.67207, 2.14981] [0.86069, 1.10661] [2.03310, 1.78879] [1.06607, 0.90123]
    0.75 0.6 [2.59311, 3.33400] [1.43871, 1.84977] [3.11282, 2.81429] [1.75703, 1.53144]
    0.8 [3.65583, 4.70036] [2.14470, 2.75747] [4.34716, 4.00903] [2.58875, 2.31341]
    1.0 [4.88892, 6.28575] [3.00699, 3.86613] [5.77144, 5.40324] [3.59459, 3.27853]

     | Show Table
    DownLoad: CSV

    Application 2. ([32]) Consider an electrical RL circuit with an AC source

    Pβψ(t)=RLψ(t)+Ω(t), 0t1, β(0,1], (5.23)

    subject to the following F-IC:

    ψ(0)=ω, (5.24)

    Suppose that R=1 Ohm, L=1 Henry, Ω(t)=sin(tβ), and ω(κ)={25κ24,0.96κ1;101100κ,1κ1.01;0,otherwise. Then,

    Case 1: When ψ(t) is (1;β)-FCD, the crisp system of the fuzzy conformable IVPs (5.23) and (5.24) can be expressed in the following form:

    Pβψ_(t)=¯ψ(t)+sin(tβ),Pβ¯ψ(t)=ψ_(t)+sin(tβ), (5.25)

    subject to the following F-ICs:

    ψ_(0)=2425+125,¯ψ(0)=101100+1100. (5.26)

    By applying the L-RPSM, we can express the FCL transform of the crisp system described in Eq (5.25) as follows:

    Ψ_(s)(2425+125)1s+¯Ψ(s)sβs(β2+s2)=0,¯Ψ(s)(101100+1100)1s+Ψ_(s)sβs(β2+s2)=0, (5.27)

    where Ψ_(s)=Lβ[ψ_(t)] and ¯Ψ(s)=Lβ[¯ψ(t)].

    In this particular arrangement, the expansions given in Eq (5.27) can also be represented by the fuzzy series solutions as:

    Ψ_(s)=(2425+125)1s+m=1msm+1,¯Ψ(s)=(101100+1100)1s+m=1msm+1. (5.28)

    And thus, the representation of the FCL residual functions for the crisp system in Eq (5.27) takes the form of fuzzy expressions as:

    LRes_(s)=(β2+s2)sΨ_(s)(2425+125)(β2+s2)s2+(β2+s2)¯Ψ(s)s2βs2,¯LRes(s)=(β2+s2)s¯Ψ(s)(101100+1100)(β2+s2)s2+(β2+s2)Ψ_(s)s2βs2. (5.29)

    Let us substitute the series solution expansions from Eq (5.28) into the FCL residual functions presented in Eq (5.29), yielding the following representation:

    LRes_(s)=(β2+s2)m=1msm+2+(β2+s2)m=0msm+3βs2=1+0s+2+1βs2+m=3m+m1+β2m2+β2m3sm, s>0,¯LRes(s)=(β2+s2)m=1msm+2+(β2+s2)m=0msm+3βs2=1+0s+2+1βs2+m=3m+m1+β2m2+β2m3sm, s>0. (5.30)

    As LRes_(s)=0 and ¯LRes(s)=0, the values of the coefficients m and m, m=0,1,2, are determined by the following recurrence relation:

    0=(2425+125),1=0,2=1+β,m=(m1+β2m2+β2m3), m=3,4,5,, (5.31)

    and

    0=(101100+1100),1=0,2=1+β,m=(m1+β2m2+β2m3), m=3,4,5,. (5.32)

    To obtain the solutions of Eq (5.27) in FCL space, calculate and substitute the values of the coefficients m and m, m=1,2, back into Eq (5.28). The resulting solutions can be expressed in the following series form:

    Ψ_(s)=0s0s2+0+βs30+βs4+0+ββ3s50+ββ3s6+,¯Ψ(s)=0s0s2+0+βs30+βs4+0+ββ3s50+ββ3s6+. (5.33)

    By applying the inverse FCL transform to the expansions provided in Eq (5.33), and rearranging the resulting terms, we can obtain the exact solutions of IVPs (5.25) and (5.26) in the original space as follows:

    ψ_(t)=00βtβ+0+ββ2(2)!t2β0+ββ3(3)!t3β+0+ββ3β4(4)!t4β+=m=0((0+m1k=0(1)kβ2k+1)t2mββ2m(2m)!)m=0((0+m1k=0(1)kβ2k+1)t(2m+1)ββ2m+1(2m+1)!)=0cosh(tββ)0sinh(tββ)+11+β2(sin(tβ)βcos(tβ))+βetββ1+β2,¯ψ(t)=00βtβ+0+ββ2(2)!t2β0+ββ3(3)!t3β+0+ββ3β4(4)!t4β+=m=0((0+m1k=0(1)kβ2k+1)t2mββ2m(2m)!)m=0((0+m1k=0(1)kβ2k+1)t(2m+1)ββ2m+1(2m+1)!)=0cosh(tββ)0sinh(tββ)+11+β2(sin(tβ)βcos(tβ))+βetββ1+β2. (5.34)

    When considering the standard case where β=1, Eq (5.34) can be expressed in the following form:

    ψ_(t)=0cosh(t)0sinh(t)+12(sin(t)cos(t))+12et,¯ψ(t)=0cosh(t)0sinh(t)+12(sin(t)cos(t))+12et. (5.35)

    Hence, these expressions above correspond to the exact solutions of the IVPs (5.25) and (5.26) in ordinary derivative:

    [ψ(t)]=12(sin(t)cos(t))+12et+cosh(t)[ω]sinh(t)[ω],

    where [ω]=[2425+125,101100+1100].

    Case 2: If ψ(t) is an (2;β)-FCD function, we can represent the crisp system of fuzzy conformable IVPs (5.23) and (5.24) using the following form:

    Pβψ_(t)=ψ_(t)+sin(tβ),Pβ¯ψ(t)=¯ψ(t)+sin(tβ), (5.36)

    subject to the following F-ICs:

    ψ_(0)=2425+125,¯ψ(0)=101100+1100. (5.37)

    By employing the L-RPSM, the FCL transform of the crisp system described in Eq (5.36) can be expressed as:

    Ψ_(s)(2425+125)1s+Ψ_(s)sβs(β2+s2)=0,¯Ψ(s)(101100+1100)1s+¯Ψ(s)sβs(β2+s2)=0, (5.38)

    where Ψ_(s)=Lβ[ψ_(t)] and ¯Ψ(s)=Lβ[¯ψ(t)].

    In a similar vein, we can depict the fuzzy series solutions of the expansions presented in Eq (5.38) in the following manner:

    Ψ_(s)=(2425+125)1s+m=1msm+1,¯Ψ(s)=(101100+1100)1s+m=1msm+1, (5.39)

    and the FCL residual functions of the crisp system in Eq (5.38) is represented as:

    LRes_(s)=(β2+s2)sΨ_(s)(2425+125)(β2+s2)s2+(β2+s2)Ψ_(s)s2βs2,¯LRes(s)=(β2+s2)s¯Ψ(s)(101100+1100)(β2+s2)s2+(β2+s2)¯Ψ(s)s2βs2. (5.40)

    By performing the substitution of the series solution expansions from Eq (5.39) into the FCL residual functions described in Eq (5.40), we obtain the following representation:

    LRes_(s)=(β2+s2)m=1msm+2+(β2+s2)m=0msm+3βs2=1+0s+2+1βs2+m=3m+m1+β2m2+β2m3sm,¯LRes(s)=(β2+s2)m=1msm+2+(β2+s2)m=0msm+3βs2=1+0s+2+1βs2+m=3m+m1+β2m2+β2m3sm. (5.41)

    Given that LRes_(s)=0 and ¯LRes(s)=0, the recurrence relation that determines the values of the coefficients m and m, m=0,1,2, can be expressed as:

    0=(2425+125),1=0,2=1+β,m=(m1+β2m2+β2m3), m=3,4,5,, (5.42)

    and

    0=(101100+1100),1=0,2=1+β,m=(m1+β2m2+β2m3), m=3,4,5,. (5.43)

    Compute the values of the coefficients m and m, m=1,2,, and then substitute them back into Eq (5.39). This process results in the solutions of Eq (5.38) in FCL space, expressed in the following series form:

    Ψ_(s)=0s0s2+0+βs30+βs4+0+ββ3s50+ββ3s6+,¯Ψ(s)=0s0s2+0+βs30+βs4+0+ββ3s50+ββ3s6+. (5.44)

    Upon applying the inverse FCL transform to the expansions provided in Eq (5.44), and subsequently rearranging the terms, we can present the exact solutions of IVPs (5.36) and (5.37) in the original space as follows:

    ψ_(t)=00βtβ+0+ββ2(2)!t2β0+ββ3(3)!t3β+0+ββ3β4(4)!t4β+=m=0((0+m1k=0(1)kβ2k+1)t2mββ2m(2m)!)m=0((0+m1k=0(1)kβ2k+1)t(2m+1)ββ2m+1(2m+1)!)=0etββ+11+β2(sin(tβ)βcos(tβ))+βetββ1+β2,¯ψ(t)=00βtβ+0+ββ2(2)!t2β0+ββ3(3)!t3β+0+ββ3β4(4)!t4β+=m=0((0+m1k=0(1)kβ2k+1)t2mββ2m(2m)!)m=0((0+m1k=0(1)kβ2k+1)t(2m+1)ββ2m+1(2m+1)!)=0etββ+11+β2(sin(tβ)βcos(tβ))+βetββ1+β2. (5.45)

    In the case of \beta = 1 , Eq (5.45) can be expressed in the following form:

    \begin{equation} \begin{split} \underline{\psi}_{\wp}(t) = &\Im_0e^{-t}+\frac{1}{2}\big(\sin{(t)}-\cos{(t)}\big)+\frac{1}{2}e^{-t},\\ \overline{\psi}_{\wp}(t) = &\ell_0e^{-t}+\frac{1}{2}\big(\sin{(t)}-\cos{(t)}\big)+\frac{1}{2}e^{-t}, \end{split} \end{equation} (5.46)

    which are equivalent to the exact solutions of the IVPs (5.36) and (5.37) in ordinary derivative:

    \begin{equation*} [\psi(t)]_{\wp} = \frac{1}{2}\big(\sin{(t)}-\cos{(t)}\big)+\frac{1}{2}e^{-t}+ e^{-t}[\omega]_{\wp}, \end{equation*}

    where [\omega]_{\wp} = \Big[\frac{24}{25}+\frac{1}{25}\wp, \frac{101}{100}+\frac{1}{100}\wp\Big] . Figure 3 presents the surface graphs of the solutions of Application 2 for both cases at different values of \beta . Numerical simulation of the solutions is performed of Application 2 for both cases at different values of \wp and \beta with some selected grid points on the interval [0, 1] as shown in Table 2.

    Figure 3.  The surface graphs of the solutions for Application 2: (a) [\psi(t)]_\wp at \beta = 0.5 , case 1, (b) [\psi(t)]_\wp at \beta = 0.5 , case 2, (c) [\psi(t)]_\wp at \beta = 1 , case 1, (d) [\psi(t)]_\wp at \beta = 1 , case 2.
    Table 2.  Numerical results of [\underline{\psi}_\wp(t), \overline{\psi}_\wp(t)] for Application 2.
    [\underline{\psi}_\wp(t), \overline{\psi}_\wp(t)] ; \psi(t) is (1;\beta) -CFD [\underline{\psi}_\wp(t), \overline{\psi}_\wp(t)] ; \psi(t) is (2;\beta) -CFD
    \wp t \beta=0.75 \beta=1 \beta=0.75 \beta=1
    0.1 [0.77453, 0.82840] [0.87827, 0.92524] [0.78470, 0.81823] [0.88253, 0.92098]
    0.3 [0.63176, 0.70472] [0.74615, 0.80352] [0.65586, 0.68062] [0.75910, 0.79058]
    0.25 0.5 [0.57979, 0.67370] [0.67038, 0.74045] [0.61713, 0.63636] [0.69252, 0.71830]
    0.7 [0.56856, 0.68646] [0.63743, 0.72301] [0.61985, 0.63517] [0.66967, 0.69077]
    0.9 [0.57780, 0.72350] [0.63489, 0.73942] [0.64445, 0.65685] [0.67852, 0.69580]
    0.1 [0.79390, 0.82875] [0.89787, 0.92826] [0.80048, 0.82217] [0.90062, 0.92551]
    0.3 [0.65191, 0.69913] [0.76554, 0.80266] [0.66751, 0.68353] [0.77391, 0.79428]
    0.75 0.5 [0.60202, 0.66279] [0.69032, 0.73566] [0.62618, 0.63863] [0.70465, 0.72133]
    0.7 [0.59387, 0.67016] [0.65874, 0.71412] [0.62706, 0.63697] [0.67960, 0.69326]
    0.9 [0.60716, 0.70143] [0.65842, 0.72606] [0.65028, 0.65831] [0.68665, 0.69783]

     | Show Table
    DownLoad: CSV

    Application 3. ([31,32]) Consider the following fuzzy conformable fractional IVPs

    \begin{equation} \begin{split} \mathfrak{P}^\beta\psi(t) = 2t^\beta\psi(t)+ [\wp-1,1-\wp] t^\beta, \ 0 \leq t \leq 1, \ \beta\in (0,1], \end{split} \end{equation} (5.47)

    subject to the following F-IC:

    \begin{equation} \begin{split} \psi(0) = [\wp-1,1-\wp], \end{split} \end{equation} (5.48)

    where \wp\in[0, 1] .

    Case 1: If \psi(t) is (1;\beta) -FCD, then the crisp system of the fuzzy conformable fractional IVPs (5.47) and (5.48) can be written in the following form:

    \begin{equation} \begin{split} \mathfrak{P}^\beta\underline{\psi}_{\wp}(t) = &2t^\beta\underline{\psi}_{\wp}(t)+(\wp-1) t^\beta,\\ \mathfrak{P}^\beta\overline{\psi}_{\wp}(t) = &2t^\beta\overline{\psi}_{\wp}(t)+(1-\wp) t^\beta, \end{split} \end{equation} (5.49)

    subject to the following F-ICs:

    \begin{equation} \begin{split} \underline{\psi}_{\wp}(0) = &(\wp-1),\\ \overline{\psi}_{\wp}(0) = &(1-\wp). \end{split} \end{equation} (5.50)

    According to Algorithm 1, the initial step involves applying the FCL transform to the crisp system described in Eq (5.49). The resulting transformed form can be represented as:

    \begin{equation} \begin{split} \underline{\Psi}_\wp(s)-\frac{(\wp-1)}{s}+\frac{2\beta}{s}\frac{d}{ds}\underline{\Psi}_\wp(s)-\frac{(\wp-1)\beta}{s^{3}} = &0,\\ \overline{\Psi}_\wp(s)-\frac{(1-\wp)}{s}+\frac{2\beta}{s}\frac{d}{ds}\overline{\Psi}_\wp(s)-\frac{(1-\wp)\beta}{s^{3}} = &0, \end{split} \end{equation} (5.51)

    where \underline{\Psi}_\wp(s) = \mathfrak{L}_\beta\Big[\underline{\psi}_\wp(t)\Big] and \overline{\Psi}_\wp(s) = \mathfrak{L}_\beta\Big[\overline{\psi}_\wp(t)\Big] .

    In this orientation as well, the fuzzy series solutions of the expansions in Eq (5.51) can be written as:

    \begin{equation} \begin{split} \underline{\Psi}_{\wp}(s) = &\frac{(\wp-1)}{s}+\sum\limits_{m = 1}^{\infty}{\frac{\Im_m}{s^{m+1}}},\\ \overline{\Psi}_{\wp}(s) = &\frac{(1-\wp)}{s}+\sum\limits_{m = 1}^{\infty}{\frac{\ell_m}{s^{m+1}}}, \end{split} \end{equation} (5.52)

    and the FCL residual functions of the crisp system in Eq (5.51) is represented as:

    \begin{equation} \begin{split} \underline{LRes}_\wp(s) = &\underline{\Psi}_\wp(s)-\frac{(\wp-1)}{s}+\frac{2\beta}{s}\frac{d}{ds}\underline{\Psi}_\wp(s)-\frac{(\wp-1)\beta}{s^{3}},\\ \overline{LRes}_\wp(s) = &\overline{\Psi}_\wp(s)-\frac{(1-\wp)}{s}+\frac{2\beta}{s}\frac{d}{ds}\overline{\Psi}_\wp(s)-\frac{(1-\wp)\beta}{s^{3}}. \end{split} \end{equation} (5.53)

    Substitute the expansions of series solution in Eq (5.52) into the FCL residual functions in Eq (5.53), respectively, as:

    \begin{equation} \begin{split} \underline{LRes}_\wp(s) = &\sum\limits_{m = 1}^{\infty}{\frac{\Im_m}{s^{m+1}}}-2\beta\sum\limits_{m = 0}^{\infty}{\frac{(m+1)\Im_m}{s^{m+3}}}-\frac{(\wp-1)\beta}{s^{3}}\\ = &\frac{\Im_1}{s^{2}}+\frac{\Im_2-3\beta(\wp-1)}{s^{3}}+\sum\limits_{m = 3}^{\infty}{\frac{\Im_m-2\beta(m-1)\Im_{m-2}}{s^{m+1}}},\ s > 0,\\ \overline{LRes}_\wp(s) = &\sum\limits_{m = 1}^{\infty}{\frac{\ell_m}{s^{m+1}}}-2\beta\sum\limits_{m = 0}^{\infty}{\frac{(m+1)\ell_m}{s^{m+3}}}-\frac{(1-\wp)\beta}{s^{3}}\\ = &\frac{\ell_1}{s^{2}}+\frac{\ell_2-3\beta(1-\wp)}{s^{3}}+\sum\limits_{m = 3}^{\infty}{\frac{\ell_m-2\beta(m-1)\ell_{m-2}}{s^{m+1}}},\ s > 0. \end{split} \end{equation} (5.54)

    Since \underline{LRes}_\wp(s) = 0 and \overline{LRes}_\wp(s) = 0 , the recurrence relation which determines the values of the coefficients \Im_m and \ell_m, \ m = 0, 1, 2, \ldots given by:

    \begin{equation} \begin{split} \Im_0 = &(\wp-1),\\ \Im_1 = &0,\\ \Im_2 = &3\beta(\wp-1),\\ \Im_m = &2\beta(m-1)\Im_{m-2},\ m = 3,4,5,\ldots, \end{split} \end{equation} (5.55)

    and

    \begin{equation} \begin{split} \ell_0 = &(1-\wp),\\ \ell_1 = &0,\\ \ell_2 = &3\beta(1-\wp),\\ \ell_m = &2\beta(m-1)\ell_{m-2},\ m = 3,4,5,\ldots. \end{split} \end{equation} (5.56)

    Compute and substitute the values of the coefficients \Im_m and \ell_m, \ m = 1, 2, \ldots back into Eq (5.52) to have the solutions of Eq (5.51) in FCL space as following series form:

    \begin{equation} \begin{split} \underline{\Psi}_{\wp}(s) = &\frac{(\wp-1)}{s}+\frac{3\beta(\wp-1)}{s^{3}}+\frac{18\beta^{2}(\wp-1)}{s^{5}}+\frac{180\beta^{3}(\wp-1)}{s^{7}}+\cdots,\\ \overline{\Psi}_{\wp}(s) = &\frac{(1-\wp)}{s}+\frac{3\beta(1-\wp)}{s^{3}}+\frac{18\beta^{2}(1-\wp)}{s^{5}}+\frac{180\beta^{3}(1-\wp)}{s^{7}}+\cdots. \end{split} \end{equation} (5.57)

    Employ the inverse FCL transform into the expansions in Eq (5.57) to have the exact solutions of IVPs (5.49) and (5.50) in original space as follows:

    \begin{equation} \begin{split} \underline{\psi}_{\wp}(t) = &(\wp-1)+\frac{3(\wp-1)}{\beta(2)!}t^{2\beta}+\frac{18\beta(\wp-1)}{\beta^2(4)!}t^{4\beta}+\frac{180\beta(\wp-1)}{\beta^3(6)!}t^{6\beta}+\cdots\\ = &\frac{1}{2} \Bigg(3\sum\limits_{m = 0}^{\infty}{\frac{t^{2m\beta}}{\beta^m(m)!}}-1\Bigg)(\wp-1) = \frac{1}{2}(\wp-1)\big(3e^{\frac{t^{2\beta}}{\beta}}-1\big),\\ \overline{\psi}_{\wp}(t) = &(1-\wp)+\frac{3(1-\wp)}{\beta(2)!}t^{2\beta}+\frac{18\beta(1-\wp)}{\beta^2(4)!}t^{4\beta}+\frac{180\beta(1-\wp)}{\beta^3(6)!}t^{6\beta}+\cdots\\ = &\frac{1}{2} \Bigg(3\sum\limits_{m = 0}^{\infty}{\frac{t^{2m\beta}}{\beta^m(m)!}}-1\Bigg)(1-\wp) = \frac{1}{2}(1-\wp)\big(3e^{\frac{t^{2\beta}}{\beta}}-1\big). \end{split} \end{equation} (5.58)

    For the standard case \beta = 1 , Eq (5.58) have the following form:

    \begin{equation} \begin{split} \underline{\psi}_{\wp}(t) = &\frac{1}{2} \Bigg(3\sum\limits_{m = 0}^{\infty}{\frac{t^{2m}}{(m)!}}-1\Bigg)(\wp-1) = \frac{1}{2}(\wp-1)\big(3e^{t^2}-1\big),\\ \overline{\psi}_{\wp}(t) = &\frac{1}{2} \Bigg(3\sum\limits_{m = 0}^{\infty}{\frac{t^{2m}}{(m)!}}-1\Bigg)(1-\wp) = \frac{1}{2}(1-\wp)\big(3e^{t^2}-1\big), \end{split} \end{equation} (5.59)

    which are equivalent to the exact solutions [\psi(t)]_{\wp} = \frac{1}{2}[\wp-1, 1-\wp]\big(3e^{t^2}-1\big) of the IVPs (5.49) and (5.50) in ordinary derivative.

    Case 2: If \psi(t) is (2;\beta) -FCD, then the crisp system of the fuzzy conformable fractional IVPs (5.47) and (5.48) can be written in the following form:

    \begin{equation} \begin{split} \mathfrak{P}^\beta\underline{\psi}_{\wp}(t) = &2t^\beta\overline{\psi}_{\wp}(t)+(1-\wp) t^\beta,\\ \mathfrak{P}^\beta\overline{\psi}_{\wp}(t) = &2t^\beta\underline{\psi}_{\wp}(t)+(\wp-1) t^\beta, \end{split} \end{equation} (5.60)

    subject to the following F-ICs:

    \begin{equation} \begin{split} \underline{\psi}_{\wp}(0) = &(\wp-1),\\ \overline{\psi}_{\wp}(0) = &(1-\wp). \end{split} \end{equation} (5.61)

    The FCL transform of the crisp system in Eq (5.60) takes the form:

    \begin{equation} \begin{split} \underline{\Psi}_\wp(s)-\frac{(\wp-1)}{s}+\frac{2\beta}{s}\frac{d}{ds}\overline{\Psi}_\wp(s)-\frac{(1-\wp)\beta}{s^{3}} = &0,\\ \overline{\Psi}_\wp(s)-\frac{(1-\wp)}{s}+\frac{2\beta}{s}\frac{d}{ds}\underline{\Psi}_\wp(s)-\frac{(\wp-1)\beta}{s^{3}} = &0, \end{split} \end{equation} (5.62)

    where \underline{\Psi}_\wp(s) = \mathfrak{L}_\beta\Big[\underline{\psi}_\wp(t)\Big] and \overline{\Psi}_\wp(s) = \mathfrak{L}_\beta\Big[\overline{\psi}_\wp(t)\Big] .

    Let us represent the fuzzy series solutions of the expansions in Eq (5.62) in the following arrangement:

    \begin{equation} \begin{split} \underline{\Psi}_{\wp}(s) = &\frac{(\wp-1)}{s}+\sum\limits_{m = 1}^{\infty}{\frac{\Im_m}{s^{m+1}}},\\ \overline{\Psi}_{\wp}(s) = &\frac{(1-\wp)}{s}+\sum\limits_{m = 1}^{\infty}{\frac{\ell_m}{s^{m+1}}}, \end{split} \end{equation} (5.63)

    and the FCL residual functions of the crisp system in Eq (5.62) is represented as:

    \begin{equation} \begin{split} \underline{LRes}_\wp(s) = &\underline{\Psi}_\wp(s)-\frac{(\wp-1)}{s}+\frac{2\beta}{s}\frac{d}{ds}\overline{\Psi}_\wp(s)-\frac{(1-\wp)\beta}{s^{3}},\\ \overline{LRes}_\wp(s) = &\overline{\Psi}_\wp(s)-\frac{(1-\wp)}{s}+\frac{2\beta}{s}\frac{d}{ds}\underline{\Psi}_\wp(s)-\frac{(\wp-1)\beta}{s^{3}}. \end{split} \end{equation} (5.64)

    Substitute the expansions of series solution in Eq (5.63) into the FCL residual functions in Eq (5.64), respectively, as:

    \begin{equation} \begin{split} \underline{LRes}_\wp(s) = &\sum\limits_{m = 1}^{\infty}{\frac{\Im_m}{s^{m+1}}}-2\beta\sum\limits_{m = 0}^{\infty}{\frac{(m+1)\ell_m}{s^{m+3}}}-\frac{(1-\wp)\beta}{s^{3}}\\ = &\frac{\Im_1}{s^{2}}+\frac{\Im_2-3\beta(1-\wp)}{s^{3}}+\sum\limits_{m = 3}^{\infty}{\frac{\Im_m-2\beta(m-1)\ell_{m-2}}{s^{m+1}}},\ s > 0,\\ \overline{LRes}_\wp(s) = &\sum\limits_{m = 1}^{\infty}{\frac{\ell_m}{s^{m+1}}}-2\beta\sum\limits_{m = 0}^{\infty}{\frac{(m+1)\Im_m}{s^{m+3}}}-\frac{(\wp-1)\beta}{s^{3}}\\ = &\frac{\ell_1}{s^{2}}+\frac{\ell_2-3\beta(\wp-1)}{s^{3}}+\sum\limits_{m = 3}^{\infty}{\frac{\ell_m-2\beta(m-1)\Im_{m-2}}{s^{m+1}}},\ s > 0. \end{split} \end{equation} (5.65)

    Considering that \underline{LRes}_\wp(s) = 0 and \overline{LRes}_\wp(s) = 0 , the coefficients \Im_m and \ell_m, \ m = 0, 1, 2, \ldots can be determined through the following recurrence relation:

    \begin{equation} \begin{split} \Im_0 = &(\wp-1),\\ \Im_1 = &0,\\ \Im_2 = &3\beta(1-\wp),\\ \Im_m = &2\beta(m-1)\ell_{m-2},\ m = 3,4,5,\ldots, \end{split} \end{equation} (5.66)

    and

    \begin{equation} \begin{split} \ell_0 = &(1-\wp),\\ \ell_1 = &0,\\ \ell_2 = &3\beta(\wp-1),\\ \ell_m = &2\beta(m-1)\Im_{m-2},\ m = 3,4,5,\ldots. \end{split} \end{equation} (5.67)

    By computing and substituting the values of the coefficients \Im_m and \ell_m, \ m = 1, 2, \ldots back into Eq (5.63), we can express the solutions of Eq (5.62) in FCL space as the following series form:

    \begin{equation} \begin{split} \underline{\Psi}_{\wp}(s) = &\frac{(\wp-1)}{s}+\frac{3\beta(1-\wp)}{s^{3}}+\frac{18\beta^{2}(\wp-1)}{s^{5}}+\frac{180\beta^{3}(1-\wp)}{s^{7}}+\cdots,\\ \overline{\Psi}_{\wp}(s) = &\frac{(1-\wp)}{s}+\frac{3\beta(\wp-1)}{s^{3}}+\frac{18\beta^{2}(1-\wp)}{s^{5}}+\frac{180\beta^{3}(\wp-1)}{s^{7}}+\cdots. \end{split} \end{equation} (5.68)

    Employ the inverse FCL transform into the expansions in Eq (5.68) to have the exact solutions of IVPs (5.60) and (5.61) in original space as follows:

    \begin{equation} \begin{split} \underline{\psi}_{\wp}(t) = &(\wp-1)-\frac{3(\wp-1)}{\beta(2)!}t^{2\beta}+\frac{18\beta(\wp-1)}{\beta^2(4)!}t^{4\beta}-\frac{180\beta(\wp-1)}{\beta^3(6)!}t^{6\beta}+\cdots\\ = &\frac{1}{2} \Bigg(3\sum\limits_{m = 0}^{\infty}{\frac{\big(-t^{2\beta}\big)^{m}}{\beta^m(m)!}}-1\Bigg)(\wp-1) = \frac{1}{2}(\wp-1)\big(3e^{-\frac{t^{2\beta}}{\beta}}-1\big),\\ \overline{\psi}_{\wp}(t) = &(1-\wp)-\frac{3(1-\wp)}{\beta(2)!}t^{2\beta}+\frac{18\beta(1-\wp)}{\beta^2(4)!}t^{4\beta}-\frac{180\beta(1-\wp)}{\beta^3(6)!}t^{6\beta}+\cdots\\ = &\frac{1}{2} \Bigg(3\sum\limits_{m = 0}^{\infty}{\frac{\big(-t^{2\beta}\big)^{m}}{\beta^m(m)!}}-1\Bigg)(1-\wp) = \frac{1}{2}(1-\wp)\big(3e^{-\frac{t^{2\beta}}{\beta}}-1\big). \end{split} \end{equation} (5.69)

    For the standard case \beta = 1 , Eq (5.69) have the following form:

    \begin{equation} \begin{split} \underline{\psi}_{\wp}(t) = &\frac{1}{2} \Bigg(3\sum\limits_{m = 0}^{\infty}{\frac{\big(-t^{2}\big)^{m}}{(m)!}}-1\Bigg)(\wp-1) = \frac{1}{2}(\wp-1)\big(3e^{-t^2}-1\big),\\ \overline{\psi}_{\wp}(t) = &\frac{1}{2} \Bigg(3\sum\limits_{m = 0}^{\infty}{\frac{\big(-t^{2}\big)^{m}}{(m)!}}-1\Bigg)(1-\wp) = \frac{1}{2}(1-\wp)\big(3e^{-t^2}-1\big), \end{split} \end{equation} (5.70)

    which are equivalent to the exact solutions [\psi(t)]_{\wp} = \frac{1}{2}[\wp-1, 1-\wp]\big(3e^{-t^2}-1\big) of the IVPs (5.60) and (5.61) in ordinary derivative.

    Figure 4 presents the surface graphs of the solutions of Application 3 for both cases at \beta = 1 . Figure 5 provides the 2D graphs of the solutions of Application 3 at \beta = 1 for different values of \wp . The 2D graphs of the solutions at \wp = 0.5 and different values of \beta is performed of Application 3 as shown in Figure 6.

    Figure 4.  The surface graphs of the solutions for Application 3 at \beta = 1 : (a) [\psi(t)]_\wp , case 1, (b) [\psi(t)]_\wp , case 2.
    Figure 5.  The 2D graphs of the solutions for Application 3 at \beta = 1 : (a) [\psi(t)]_\wp , case 1, (b) [\psi(t)]_\wp , case 2.
    Figure 6.  The 2D graphs of the solutions for Application 3: (a) [\psi(t)]_{0.5} , case 1, (b) [\psi(t)]_{0.5} , case 2.

    In this paper, we focused on using the fuzzy conformable derivative in fractional fuzzy equations instead of other conventional FDs, such as the Caputo derivative. The solutions obtained through this approach exhibited smoothness and closely resembled ordinary derivatives. Moreover, the mathematical calculations involved in finding these solutions were relatively simpler compared to equations employing other types of FDs. This is because the fuzzy conformable FD offers several advantages.

    Furthermore, we used a new algorithm to find a series of solutions to initial problems on FFDEs in the sense of strongly generalized differentiability. We chose the L-RPSM method, which was successful in finding an exact solution in general. The results show that the power series analysis method is a powerful and easy-to-use analytic tool to solve IVPs on FFDEs in the conformable sense.

    The authors declare they have not used Artificial Intelligence (AI) tools in the creation of this article.

    The authors sincerely thank the referees for carefully reading the manuscript and for valuable helpful suggestions. This research is funded fully by Zarqa University-Jordan.

    No potential conflict of interest was reported by the authors.

    [1] Das S, Dawson NL, Orengo RA (2015) Diversity in protein domain superfamilies. Curr Opin Genet Dev 35: 40–49.  doi: 10.1016/j.gde.2015.09.005
    [2] Giuroiu I, Weber J (2017) Novel checkpoints and cosignaling molecules in cancer immunotherapy. Cancer J 23: 23–31.  doi: 10.1097/PPO.0000000000000241
    [3] Wei SC, Levine JH, Cogdill AP, et al. (2017) Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170: 1120–1133.  doi: 10.1016/j.cell.2017.07.024
    [4] Murmann AE, McMahon KM, Haluck-Kangas A, et al. (2017) Induction of DISE in ovarian cancer cells in vivo. Oncotarget 8: 84643–84658.
    [5] Buchbinder E, Desai A (2016) CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 39: 98–106.  doi: 10.1097/COC.0000000000000239
    [6] Rotte A, Jin JY, Lemaire V (2017) Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol. 
    [7] Zelensky AN, Gready JE (2005) The C-type lectin-like domain superfamily. FEBS J 272: 6179–6217.  doi: 10.1111/j.1742-4658.2005.05031.x
    [8] Geijtenbeek TB, Gringhuis SI (2009) Signaling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 9: 465–479.  doi: 10.1038/nri2569
    [9] García-Vallejo JJ, Van KY (2009) Endogenous ligands for C-type lectin receptors: the true regulators of immune homeostasis. Immunol Rev 230: 22–37.  doi: 10.1111/j.1600-065X.2009.00786.x
    [10] Van KY, Ilarregui JM, van Vliet SJ (2015) Novel insights into the immunomodulatory role of the dendritic cell and macrophage-expressed C-type lectin MGL. Immunobiology 220: 185–192.  doi: 10.1016/j.imbio.2014.10.002
    [11] Sancho D, Reis SC (2013) Sensing of cell death by myeloid C-type lectin receptors. Curr Opin Immunol 25: 46–52.  doi: 10.1016/j.coi.2012.12.007
    [12] Chang SY, Kweon MN (2010) Langerin-expressing dendritic cells in gut-associated lymphoid tissues. Immunol Rev 234: 233–246.  doi: 10.1111/j.0105-2896.2009.00878.x
    [13] Ingeborg SO, Unger WWJ, Yvette VK (2011) C-type lectin receptors for tumor eradication: future directions. Cancers 3: 3169–3188.  doi: 10.3390/cancers3033169
    [14] Zhang F, Ren S, Zuo Y (2014) DC-SIGN, DC-SIGNR and LSECtin: C-type lectins for infection. Int Rev Immunol 33: 54–66.  doi: 10.3109/08830185.2013.834897
    [15] Yan H, Kamiya T, Suabjakyong P, et al. (2015) Targeting C-type lectin receptors for cancer immunity. Front Immunol 6: 408–416. 
    [16] Dambuza IM, Brown GD (2015) C-type lectins in immunity: recent developments. Curr Opin Immunol 32: 21–27.  doi: 10.1016/j.coi.2014.12.002
    [17] Ding D, Yao Y, Zhang S, et al. (2017) C-type lectins facilitate tumor metastasis. Oncol Lett 13: 13–21. 
    [18] Andersen CBF, Moestrup SK (2014) How calcium makes endocytic receptors attractive. Trends Biochem Sci 39: 82–90.  doi: 10.1016/j.tibs.2013.12.003
    [19] Eggensperger A, Tampé R (2015) The transporter associated with antigen processing: a key player in adaptive immunity. Biol Chem 396: 1059–1072. 
    [20] Rodriguez A, Regnault A, Kleijmeer M, et al. (1999) Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1: 362–368.  doi: 10.1038/14058
    [21] Solheim JC (1999) Class I MHC molecules: assembly and antigen presentation. Immunol Rev 172: 11–19.  doi: 10.1111/j.1600-065X.1999.tb01352.x
    [22] Gil-Torregrosa BC, Lennon-Duménil AM, Kessler B, et al. (2004) Control of cross-presentation during dendritic cell maturation. Eur J Immunol 34: 398–407.  doi: 10.1002/eji.200324508
    [23] Heath WR, Carbone FR (2001) Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol 1: 126–135.  doi: 10.1038/35100512
    [24] Joffre OP, Segura E, Savina A, et al. (2012) Cross-presentation by dendritic cells. Nat Rev Immunol 12: 557–569.  doi: 10.1038/nri3254
    [25] McDonnell AM, Robinson BWS, Currie AJ (2010) Tumor antigen cross-presentation and the dendritic cell: where it all begins? Clin Dev Immunol 2010: 539519–539527. 
    [26] Bousso P, Robey E (2003) Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat Immunol 4: 579–585. 
    [27] Randolph GJ, Jakubzick C, Qu C (2008) Antigen presentation by monocytes and monocyte-derived cells. Curr Opin Immunol 20: 52–60.  doi: 10.1016/j.coi.2007.10.010
    [28] Leiri?o P, Fresno CD, Ardavín C (2012) Monocytes as effector cells: activated Ly-6C(high) mouse monocytes migrate to the lymph nodes through the lymph and cross-present antigens to CD8+ T cells. Eur J Immunol 42: 2042–2051.  doi: 10.1002/eji.201142166
    [29] Raghavan M, Wijeyesakere SJ, Peters LR, et al. (2013) Calreticulin in the immune system: ins and outs. Trends Immunol 34: 13–21.  doi: 10.1016/j.it.2012.08.002
    [30] Lv D, Shen Y, Peng Y, et al. (2015) Neuronal MHC class I expression is regulated by activity driven calcium signaling. PLoS One 10: e0135223–e0135238.  doi: 10.1371/journal.pone.0135223
    [31] Skov S (1999) Intracellular signal transduction mediated by ligation of MHC class I molecules. Tissue Antigens 51: 215–223. 
    [32] Blum JS, Wearsch PA, Cresswell P (2013) Pathways of antigen processing. Annu Rev Immunol 31: 443–473.  doi: 10.1146/annurev-immunol-032712-095910
    [33] Roche PA, Furuta K (2015) The ins and outs of MHC class II-mediated antigen processing and presentation. Nat Rev Immunol 15: 203–216.  doi: 10.1038/nri3818
    [34] Mueller SN (2017) Spreading the load: antigen transfer between migratory and lymph node-resident dendritic cells promotes T-cell priming. Eur J Immunol 47: 1798–1801.  doi: 10.1002/eji.201747248
    [35] Parton RG, Joggerst B, Simons K (1994) Regulated internalization of caveolae. J Cell Biol 127: 1199–1215.  doi: 10.1083/jcb.127.5.1199
    [36] Levine TP, Chain BM (1992) Endocytosis by antigen presenting cells: dendritic cells are as endocytically active as other antigen presenting cells. Proc Natl Acad Sci USA 89: 8342–8346.  doi: 10.1073/pnas.89.17.8342
    [37] Hohn C, Lee SR, Pinchuk LM, et al. (2009) Zebrafish kidney phagocytes utilize macropinocytosis and Ca+-dependent endocytic mechanisms. PLoS One 4: e4314–e4323.  doi: 10.1371/journal.pone.0004314
    [38] Calmette J, Bertrand M, Vétillard M, et al. (2016) Glucocorticoid-induced leucine zipper protein controls macropinocytosis in dendritic cells. J Immunol 197: 4247–4256.  doi: 10.4049/jimmunol.1600561
    [39] Ayroldi E, Riccardi C (2009) Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J 23: 3649–3658.  doi: 10.1096/fj.09-134684
    [40] Ronchetti S, Migliorati G, Riccardi C (2015) GILZ as a mediator of the anti-inflammatory effects of glucocorticoids. Front Endocrinol 6: 170–175. 
    [41] Canton J, Schlam D, Breuer C, et al. (2016) Calcium-sensing receptors signal constitutive macropinocytosis and facilitate the uptake of NOD2 ligands in macrophages. Nat Commun 7: 11284–11295.  doi: 10.1038/ncomms11284
    [42] Redka DS, Gütschow M, Grinstein S, et al. (2017) Differential ability of pro-inflammatory and anti-inflammatory macrophages to perform macropinocytosis. Mol Biol Cell pii: mbc.E17-06-0419. 
    [43] Carafoli E, Krebs J (2016) Why calcium? How calcium became the best communicator. J Biol Chem 291: 20849–20857. 
    [44] Caroppo R, Gerbino A, Fistetto G, et al. (2004) Extracellular calcium acts as a "third messenger" to regulate enzyme and alkaline secretion. J Cell Biol 166: 111–119.  doi: 10.1083/jcb.200310145
    [45] Drickamer K (1988) Two distinct classes of carbohydrate-recognition domains in animal lectins. J Biol Chem 263: 9557–9560. 
    [46] Drickamer K (1996) Ca(2+)-dependent sugar recognition by animal lectins. Biochem Soc T 24: 146–150.  doi: 10.1042/bst0240146
    [47] Weis WI, Taylor ME, Drickamer K (1998) The C-type lectin superfamily in the immune system. Immunol Rev 163: 19–34.  doi: 10.1111/j.1600-065X.1998.tb01185.x
    [48] Drickamer K, Taylor ME (2015) Recent insights into structures and functions of C-type lectins in the immune system. Curr Opin Struc Biol 34: 26–34.  doi: 10.1016/j.sbi.2015.06.003
    [49] van Vliet SJ, Saeland E, Van KY (2008) Sweet preferences of MGL: carbohydrate specificity and function. Trends Immunol 29: 83–90.  doi: 10.1016/j.it.2007.10.010
    [50] Van DD, Stolk DA, Van RVD, et al. (2017) Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines. J Leukocyte Biol 102: 1017–1034.  doi: 10.1189/jlb.5MR0217-059RR
    [51] Napoletano C, Zizzari IG, Rughetti A, et al. (2012) Targeting of macrophage galactose-type C-type lectin (MGL) induces DC signaling and activation. Eur J Immunol 42: 936–945.  doi: 10.1002/eji.201142086
    [52] Engering A, Geijtenbeck TBH, van Vliet SJ, et al. (2002) The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J Immunol 168: 2118–2126.  doi: 10.4049/jimmunol.168.5.2118
    [53] Database of human proteins containing CTLDs. Available from: http://www.imperial.ac.uk/research/animallectins/ctld/mammals/humandata%20updated.html. 
    [54] Cummings RD, McEver RP (2017) Chapter 34: C-Type lectins, In: Varki A, Cummings RD, Esko JD, et al., editors. Essentials of Glycobiology 3rd Ed. Cold Spring Harbor Laboratory Press, 2015–2017. 
    [55] Sancho D, Reis SC (2012) Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu Rev Immunol 30: 491–529.  doi: 10.1146/annurev-immunol-031210-101352
    [56] Billadeau DD, Leibson PJ (2002) ITAMs versus ITIMs: striking a balance during cell regulation. J Clin Invest 109: 161–168.  doi: 10.1172/JCI0214843
    [57] Ivashkiv LB (2009) Cross-regulation of signaling by ITAM-associated receptors. Nat Immunol 10: 340–347.  doi: 10.1038/ni.1706
    [58] Bezbradica JS, Rosenstein RK, DeMarco RA, et al. (2014) A role for the ITAM signaling module in specifying cytokine-receptor functions. Nat Immunol 15: 333–342.  doi: 10.1038/ni.2845
    [59] Pollitt AY, Poulter NS, Gitz E, et al. (2014) Syk and Src family kinases regulate C-type lectin receptor 2 (CLEC-2)-mediated clustering of podoplanin and platelet adhesion to lymphatic endothelial cells. J Biol Chem 289: 35695–35710.  doi: 10.1074/jbc.M114.584284
    [60] Unkeless JC, Jin J (1997) Inhibitory receptors, ITIM sequences and phosphatases. Curr Opin Immunol 9: 338–343.  doi: 10.1016/S0952-7915(97)80079-9
    [61] van Vliet SJ, Aarnoudse CA, Vc BDB, et al. (2007) MGL-mediated internalization and antigen presentation by dendritic cells: a role for tyrosine-5. Eur J Immunol 37: 2075–2081.  doi: 10.1002/eji.200636838
    [62] Harris RL, Cw VDB, Bowen DJ (2012) ASGR1 and ASGR2, the genes that encode the asialoglycoprotein receptor (Ashwell Receptor), are expressed in peripheral blood monocytes and show inter-individual differences in transcript profile. Mol Biol Int 2012: 283974–283983. 
    [63] East L, Isacke CM (2002) The mannose receptor family. BBA-Gen Subjects 1572: 364–386.  doi: 10.1016/S0304-4165(02)00319-7
    [64] Uniport. Available from: http://www.uniprot.org/uniprot/P22897.
    [65] Lo YL, Liou GG, Lyu JH, et al. (2016) Dengue virus infection is through a cooperative interaction between a mannose receptor and CLEC5A on macrophage as a multivalent hetero-complex. PLoS One 11: e0166474–e0166486.  doi: 10.1371/journal.pone.0166474
    [66] R?dgaard-Hansen S, Rafique A, Christensen PA, et al. (2014) A soluble form of the macrophage-related mannose receptor (MR/CD206) is present in human serum and elevated in critical illness. Clin Chem Lab Med 52: 453–461. 
    [67] Feinberg H, Park-Snyder S, Kolatkar AR, et al. (2000) Structure of a C-type carbohydrate recognition domain from the macrophage mannose receptor. J Biol Chem 275: 21539–21548. doi: 10.1074/jbc.M002366200
    [68] Ng KKS, Park-Snyder S, Weis WI (1998) Ca2+-dependent structural changes in C-type mannose-binding proteins. Biochemistry 37: 17965–17976.  doi: 10.1021/bi981972a
    [69] Iobst ST, Wormald MR, Weis WI, et al. (1994) Binding of sugar ligands to Ca(2+)-dependent animal lectins. I. Analysis of mannose binding by site-directed mutagenesis and NMR. J Biol Chem 269: 15505–15511. 
    [70] Weis WI, Drickamer K, Hendrickson WA (1992) Structure of a C-type mannose-binding protein complexed with an oligosaccharide. Nature 360: 127–134.  doi: 10.1038/360127a0
    [71] Drickamer K (1992) Engineering galactose-binding activity into a C-type mannose-binding protein. Nature 360: 183–186.  doi: 10.1038/360183a0
    [72] Apostolopoulos V, Pietersz GA, Loveland, BE, et al. (1995) Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci USA 92: 10128–10132.  doi: 10.1073/pnas.92.22.10128
    [73] Apostolopoulos V, Pietersz GA, Gordon S, et al. (2000) Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. Eur J Immunol 30: 1714–1723. doi: 10.1002/1521-4141(200006)30:6<1714::AID-IMMU1714>3.0.CO;2-C
    [74] Apostolopoulos V, Pietersz GA, Tsibanis A, et al. (2014) Dendritic cell immunotherapy: clinical outcomes. Clin Transl Immunol 3: e21–e24.  doi: 10.1038/cti.2014.14
    [75] Steinman RM, Turley S, Mellman I, et al. (2000) The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 191: 411–416.  doi: 10.1084/jem.191.3.411
    [76] Steinman RM, Hawiger D, Liu K, et al. (2003) Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann Ny Acad Sci 987: 15–25.  doi: 10.1111/j.1749-6632.2003.tb06029.x
    [77] Redmond WL, Sherman LA (2005) Peripheral tolerance of CD8 T lymphocytes. Immunity 22: 275–284.  doi: 10.1016/j.immuni.2005.01.010
    [78] Chieppa M, Bianchi G, Doni A, et al. (2003) Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program. J Immunol 171: 4552–4560.  doi: 10.4049/jimmunol.171.9.4552
    [79] Allavena P, Chieppa M, Blanchi G, et al. (2010) Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages. Clin Dev Immunol 2010: 547179–547188. 
    [80] Sharpe AH (2009) Mechanisms of costimulation. Immunol Rev 229: 5–11.  doi: 10.1111/j.1600-065X.2009.00784.x
    [81] Chen L, Flies DB (2013) Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 13: 227–242.  doi: 10.1038/nri3405
    [82] Anderson PJ, Kokame K, Sadler JE (2006) Zinc and calcium ions cooperatively modulate ADAMTS13 activity. J Biol Chem 281: 850–857.  doi: 10.1074/jbc.M504540200
    [83] Sorvillo N, Pos W, Lm VDB, et al. (2017) The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cells. Blood 119: 3828–3835. 
    [84] Mahnke K, Guo M, Lee S, et al. (2000) The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol 151: 673–683.  doi: 10.1083/jcb.151.3.673
    [85] Platt CD, Ma JK, Chalouni C, et al. (2010) Mature dendritic cells use endocytic receptors to capture and present antigens. Proc Nat Acad Sci USA 107: 4287–4292.  doi: 10.1073/pnas.0910609107
    [86] Tel J, Benitez-Ribas D, Hoosemans S, et al. (2011) DEC-205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells. Eur J Immunol 41: 1014–1023.  doi: 10.1002/eji.201040790
    [87] Hawiger D, Inaba K, Dorsett Y, et al. (2001) Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194: 769–779.  doi: 10.1084/jem.194.6.769
    [88] Ma DY, Clark EA (2009) The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol 21: 265–272.  doi: 10.1016/j.smim.2009.05.010
    [89] Lee GH, Askari A, Malietzis G, et al. (2014) The role of CD40 expression in dendritic cell in cancer biology: a systematic review. Curr Cancer Drug Tar 14: 610–620.  doi: 10.2174/1568009614666140828103253
    [90] Sartorius R, D'Apice L, Trovato M, et al. (2015) Antigen delivery by filamentous bacteriophage fd displaying an anti-DEC-205 single-chain variable fragment confers adjuvanticity by triggering a TLR9-mediated immune response. Embo Mol Med 7: 973–988.  doi: 10.15252/emmm.201404525
    [91] Melander MC, Jürgensen HJ, Madsen DH, et al. (2015) The collagen receptor uPARAP/Endo180 in tissue degradation and cancer (Review). Int J Oncol 47: 1177–1188.  doi: 10.3892/ijo.2015.3120
    [92] Sturge J (2016) Endo180 at the cutting edge of bone cancer treatment and beyond. J Pathol 238: 485–488.  doi: 10.1002/path.4673
    [93] Yuan C, Jürgensen HJ, Engelholm LH, et al. (2016) Crystal structures of the ligand-binding region of uPARAP: effect of calcium ion binding. Biochem J 473: 2359–2368.  doi: 10.1042/BCJ20160276
    [94] East L, Rushton S, Taylor ME, et al. (2002) Characterization of sugar binding by the mannose receptor family member, Endo180. J Biol Chem 277: 50469–50475.  doi: 10.1074/jbc.M208985200
    [95] Augert A, Payré C, de Launoit Y, et al. (2009) The M-type receptor PLA2R regulates senescence through the p53 pathway. Embo Rep 10: 271–277.  doi: 10.1038/embor.2008.255
    [96] Jr BLH, Bonegio RG, Lambeau G, et al. (2009) M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. New Engl J Med 361: 11–21.  doi: 10.1056/NEJMoa0810457
    [97] Takahashi S, Watanabe K, Watanabe Y, et al. (2015) C-type lectin-like domain and fibronectin-like type II domain of phospholipase A2 receptor 1 modulate binding and migratory responses to collagen. Febs Lett 589: 829–835.  doi: 10.1016/j.febslet.2015.02.016
    [98] Nolin JD, Ogden HL, Lai Y, et al. (2016) Identification of epithelial phospholipase A2 receptor 1 as a potential target in asthma. Am J Resp Cell Mol 55: 825–836.  doi: 10.1165/rcmb.2015-0150OC
    [99] Fresquet M, Jowitt TA, McKenzie EA, et al. (2017) PLA2R binds to the annexin A2-S100A10 complex in human podocytes. Sci Rep 7: 6876–6886.  doi: 10.1038/s41598-017-07028-8
    [100] Santamaria-Kisiel L, Rintala-Dempsey A, Shaw GS (2006) Calcium-dependent and -independent interactions of the S100 protein family. Biochem J 396: 201–214.  doi: 10.1042/BJ20060195
    [101] Goder V, Spiess M (2001) Topogenesis of membrane proteins: determinants and dynamics. Febs Lett 504: 87–93.  doi: 10.1016/S0014-5793(01)02712-0
    [102] Zimmerman R, Eyrisch S, Ahmad M, et al. (2011) Protein translocation across the ER membrane. BBA-Biomembranes 1808: 912–924.  doi: 10.1016/j.bbamem.2010.06.015
    [103] Feinberg H, Mitchell DA, Drickamer K, et al. (2001) Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 294: 2163–2166. doi: 10.1126/science.1066371
    [104] Mitchell DA, Fadden AJ, Drickamer K (2001) A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands. J Biol Chem 276: 28939–28945. 
    [105] Guo Y, Feinberg H, Conroy E, et al. (2004) Structural basis for distinct ligand-binding and targeting properties of the receptors DC-SIGN and DC-SIGNR. Nat Struct Mol Biol 11: 591–598.  doi: 10.1038/nsmb784
    [106] Caparrós E, Munoz P, Sierra-Filardi E, et al. (2006) DC-SIGN ligation on dendritic cells results in ERK and PI3K activation and modulates cytokine production. Blood 107: 3950–3958. doi: 10.1182/blood-2005-03-1252
    [107] Iyori M, Ohtani M, Hasebe A, et al. (2008) A role of the Ca2+ binding site of DC-SIGN in the phagocytosis of E. coli. Biochem Bioph Res Co 377: 367–372.  doi: 10.1016/j.bbrc.2008.09.142
    [108] Dos Santos á, Hadjivasiliou A, Ossa F, et al. (2017) Oligomerization domains in the glycan-binding receptors DC-SIGN and DC-SIGNR: sequence variation and stability differences. Protein Sci 26: 306–316.  doi: 10.1002/pro.3083
    [109] Dodagatta-Marri E, Mitchell DA, Pandit H, et al. (2017) Protein-protein interaction between surfactant protein D and DC-SIGN via C-type lectin domain can suppress HIV-1 transfer. Front Immunol 8: 834–845.  doi: 10.3389/fimmu.2017.00834
    [110] Chao PZ, Hsieh MS, Cheng CW, et al. (2015) Dendritic cells respond to nasopharygeal carcinoma cells through annexin A2-recognizing DC-SIGN. Oncotarget 6: 159–170.  doi: 10.18632/oncotarget.2700
    [111] Chia J, Goh G, Bard F (2016) Short O-GalNAc glycans: regulation and role in tumor development and clinical perspectives. BBA-Gen Subjects 1860: 1623–1639.  doi: 10.1016/j.bbagen.2016.03.008
    [112] Zheng J, Xiao H, Wu R (2017) Specific identification of glycoproteins bearing the Tn antigen in human cells. Angew Chem 129: 7213–7217.  doi: 10.1002/ange.201702191
    [113] Feinberg H, Torgersen D, Drickamer K, et al. (2000) Mechanism of pH-dependent N-acetylgalactosamine binding by a functional mimic of the hepatocyte asialoglycoprotein receptor. J Biol Chem 275: 35176–35184.  doi: 10.1074/jbc.M005557200
    [114] Morell AG, Gregoriadis G, Scheinberg IH, et al. (1971) The role of sialic acid in determining the survival of glycoproteins in the circulation. J Biol Chem 246: 1461–1467. 
    [115] Grewal PK (2010) The Ashwell-Morell receptor. Method Enzymol 479: 223–241.  doi: 10.1016/S0076-6879(10)79013-3
    [116] Weigel PH, Yik JHN (2002) Glycans as endocytosis signals: the cases of the asialoprotein and hyaluronan/chrondroitin sulfate receptors. BBA-Gen Subjects 1572: 341–363.  doi: 10.1016/S0304-4165(02)00318-5
    [117] Dixon LJ, Barnes M, Tang H, et al. (2013) Kupffer Cells in the Liver. Compr Physiol 3: 785–797. 
    [118] Tsuiji M, Fujimori M, Ohashi Y, et al. (2002) Molecular cloning and characterization of a novel mouse macrophage C-type lectin, mMGL2, which has a distinct carbohydrate specificity from mMGL1. J Biol Chem 277: 28892–28901.  doi: 10.1074/jbc.M203774200
    [119] Kolatkar AR, Weis WI (1996) Structural basis of galactose recognition by C-type animal lectins. J Biol Chem 271: 6679–6685.  doi: 10.1074/jbc.271.12.6679
    [120] Meier M, Bider MD, Malashkevich VN, et al. (2000) Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor. J Mol Biol 300: 857–865.  doi: 10.1006/jmbi.2000.3853
    [121] Higashi N, Fujioka K, Denda-Nagai K, et al. (2002) The macrophage C-type lectin specific for galactose/N-acetylgalactosamine is an endocytic receptor expressed on monocyte-derived immature dendritic cells. J Biol Chem 277: 20686–20693. doi: 10.1074/jbc.M202104200
    [122] Lundberg K, Rydnert F, Broos S, et al. (2016) C-type lectin receptor expression on human basophils and effects of allergen-specific immunotherapy. Scand J Immunol 84: 150–157.  doi: 10.1111/sji.12457
    [123] Vukman KV, Ravidà A, Aldridge AM, et al. (2013) Mannose receptor and macrophage galactose-type lectin are involved in Bordetella pertussis mast cell interaction. J Leukocyte Biol 94: 439–448.  doi: 10.1189/jlb.0313130
    [124] Savola P, Kelkka T, Rajala HL, et al. (2017) Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis. Nat Commun 8: 15869–15882.  doi: 10.1038/ncomms15869
    [125] Gaur P, Myles A, Misra R, et al. (2016) Intermediate monocytes are increased in enthesitis-related arthritis, a category of juvenile idiopathic arthritis. Clin Exp Immunol 187: 234–241. 
    [126] Vlismas A, Bletsa R, Mavrogianni D, et al. (2016) Microarray analyses reveal marked differences in growth factor and receptor expression between 8-cell human embryos and pluripotent stem cells. Stem Cells Dev 25: 160–177.  doi: 10.1089/scd.2015.0284
    [127] Klimmeck D, Hanssong J, Raffel S, et al. (2012) Proteomic cornerstones of hematopoietic stem cell differentiation: distinct signatures of multipotent progenitors and myeloid committed cells. Molec Cell Proteomics 11: 286–302.  doi: 10.1074/mcp.M111.016790
    [128] Winkler C, Witte L, Moraw N, et al. (2014) Impact of endobronchial allergen provocation on macrophage phenotype in asthmatics. BMC Immunol 15: 12–22. doi: 10.1186/1471-2172-15-12
    [129] Mathews JA, Kasahara DI, Ribeiro L, et al. (2015) γδ T cells are required for M2 macrophage polarization and resolution of ozone-induced pulmonary inflammation in mice. PLoS One 10: e0131236–e0131251.  doi: 10.1371/journal.pone.0131236
    [130] Shin H, Kumamoto Y, Gopinath S, et al. (2016) CD301b+ dendritic cells stimulate tissue-resident memory CD8+ T cells to protect against genital HSV-2. Nat Commun 7: 13346–13355.  doi: 10.1038/ncomms13346
    [131] Linehan JL, Dileepan T, Kashem SW, et al. (2015) Generation of Th17 cells in response to intranasal infection requires TGF-β1 from dendritic cells and IL-6 from CD301b+ dendritic cells. Proc Natl Acad Sci USA 112: 12782–12787. 132. Wong KL, Tai JJ, Wong WC, et al. (2011) Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 118: e16–e31.  doi: 10.1182/blood-2010-12-326355
    [132] 133. Wong KL, Yeap WH, Tai JJY, et al. (2012) The three human monocyte subsets: implications for health and disease. Immunol Res 53: 41–57.  doi: 10.1007/s12026-012-8297-3
    [133] 134. Michlmayr D, Andrade P, Gonzalez K, et al. (2017) CD14+CD16+ monocytes are the main target of Zika virus infection in peripheral blood mononuclear cells in a paediatric study in Nicaragua. Nat Microbiol 2: 1462–1470.  doi: 10.1038/s41564-017-0035-0
    [134] 135. Knudsen NH, Lee CH (2016) Identity crisis: CD301b(+) mononuclear phagocytes blur the M1-M2 macrophage line. Immunity 45: 461–463.  doi: 10.1016/j.immuni.2016.09.004
    [135] 136. Zhang W, Xu W, Xiong S (2011) Macrophage differentiation and polarization via phosphatidylinositol 3-kinase/Akt-ERK signaling pathway conferred by serum amyloid P component. J Immunol 187: 1764–1777.  doi: 10.4049/jimmunol.1002315
    [136] 137. Trowbridge IS, Thomas M (1994) CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annu Rev Immunol 12: 85–116.  doi: 10.1146/annurev.iy.12.040194.000505
    [137] 138. van Vliet SJ, Gringhuis SI, Geijtenbeek TBH, et al. (2006) Regulation of effector T cells by antigen-presenting cells via interaction with the C-type lectin MGL with CD45. Nat Immunol 11: 1200–1208. 
    [138] 139. Nam HJ, Poy F, Saito H, et al. (2005) Structural basis for the function and regulation of the receptor protein tyrosine phosphatase CD45. J Exp Med 201: 441–452.  doi: 10.1084/jem.20041890
    [139] 140. Xu Z, Weiss A (2002) Negative regulation of CD45 by differential homodimerization of the alternatively spliced isoforms. Nat Immunol 3: 764–771.  doi: 10.1038/ni822
    [140] 141. Kumar V, Cheng P, Condamine T, et al. (2016) CD45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation. Immunity 44: 303–315.  doi: 10.1016/j.immuni.2016.01.014
    [141] 142. van Vliet SJ, van Liempt E, Geijtenbeek TB, et al. (2006) Differential regulation of C-type lectin expression on tolerogenic dendritic cell subsets. Immunobiology 211: 577–585.  doi: 10.1016/j.imbio.2006.05.022
    [142] 143. Marcelo F, Garcia-Martin F, Matsushita T, et al. (2014) Delineating binding modes of Gal/GalNAc and structural elements of the molecular recognition of tumor-associated mucin glycopeptides by the human macrophage galactose-type lectin. Chem Eur J 20: 16147–16155.  doi: 10.1002/chem.201404566
    [143] 144. Tanaka J, Gleinich AS, Zhang Q, et al. (2017) Specific and differential binding of N-acetylgalactosamine glycopolymers to the human macrophage galactose lectin and asialoglycoprotein receptor. Biomacromolecules 18: 1624–1633.  doi: 10.1021/acs.biomac.7b00228
    [144] 145. Khorev O, Stokmaier D, Schwardt O, et al. (2008) Trivalent, Gal/GaNAc-containing ligands designed for the asialoglycoprotein receptor. Bioorg Med Chem 16: 5216–5231.  doi: 10.1016/j.bmc.2008.03.017
    [145] 146. Nair JK, Willoughby JLS, Chan A, et al. (2014) Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc 136: 16958–16961.  doi: 10.1021/ja505986a
    [146] 147. Lo-Man R, Bay S, Vichier-Guerre S, et al. (1999) A fully synthetic immunogen carrying a carcinoma-associated carbohydrate for active specific immunotherapy. Cancer Res 59: 1520–1524. 
    [147] 148. Lo-Man R, Vichier-Guerre S, Bay S, et al. (2001) Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope. J Immunol 166: 2849–2854.  doi: 10.4049/jimmunol.166.4.2849
    [148] 149. Morgan AJ, Platt FM, Lloyd-Evans E, et al. (2011) Molecular mechanisms of endolysosomal Ca2+ signaling in health and disease. Biochem J 439: 349–374.  doi: 10.1042/BJ20110949
    [149] 150. Wragg S, Drickamer K (1999) Identification of amino acid residues that determine pH dependence of ligand binding to the asialoglyprotein receptor during endocytosis. J Biol Chem 274: 35400–35406.  doi: 10.1074/jbc.274.50.35400
    [150] 151. Onizuka T, Shimizu H, Moriwaki Y, et al. (2012) NMR study of ligand release from asialoglycoprotein receptor under solution conditions in early endosomes. Febs J 279: 2645–2656.  doi: 10.1111/j.1742-4658.2012.08643.x
    [151] 152. Gerasimenko JV, Tepikin AV, Petersen OH, et al. (1998) Calcium uptake via endocytosis with rapid release from acidifying endosomes. Curr Biol 8: 1335–1338.  doi: 10.1016/S0960-9822(07)00565-9
    [152] 153. Plattner H, Verkhratsky A (2016) Inseparable tandem: evolution chooses ATP and Ca2+ to control life, death and cellular signaling. Philos T R Soc B 371: 20150419–20150433.  doi: 10.1098/rstb.2015.0419
    [153] 154. Napoletano C, Rughetti A, Tarp MPA, et al. (2007) Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells. Cancer Res 67: 8358–8367.  doi: 10.1158/0008-5472.CAN-07-1035
    [154] 155. Hiltbold EM, Vlad AM, Ciborowski P, et al. (2000) The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J Immunol 165: 3730–3741.  doi: 10.4049/jimmunol.165.7.3730
    [155] 156. Hanisch FG, Schwientek T, Von BergweltBaildon MS, (2003) O-Linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells. Eur J Immunol 33: 3242–3254.  doi: 10.1002/eji.200324189
    [156] 157. Freire T, Zhang X, Dériaud E, et al. (2010) Glycosidic Tn-based vaccines targeting dermal dendritic cells favor germinal center B-cell development and potent antibody response in the absence of adjuvant. Blood 116: 3526–3536.  doi: 10.1182/blood-2010-04-279133
    [157] 158. Freire T, Lo-Man R, Bay S, et al. (2011) Tn glycosylation of the MUC6 protein modulates its immunogenicity and promotes the induction of the Th17-biased T cell responses. J Biol Chem 286: 7797–7811.  doi: 10.1074/jbc.M110.209742
    [158] 159. Li D, Romain G, Flamar AL, et al. (2012) Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generate IL-10-producing suppressive CD4+ T cells. J Exp Med 209: 109–121.  doi: 10.1084/jem.20110399
    [159] 160. Valladeau J, Duvert-Frances V, Pin JJ, et al. (2001) Immature human dendritic cells express asialoglycoprotein receptor isoforms for efficient receptor-mediated endocytosis. J Immunol 167: 5767–5774.  doi: 10.4049/jimmunol.167.10.5767
    [160] 161. Garg S, Oran A, Wajchman J, et al. (2003) Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo. Nat Immunol 4: 907–912.
    [161] 162. Tomura M, Hata A, Matsuoka S, et al. (2014) Tracking and quantification of dendritic cell migration and antigen trafficking between the skin and lymph nodes. Sci Rep 4: 6030–6040. 
    [162] 163. Kitano M, Yamazaki C, Takumi A, et al. (2016) Imaging of the cross-presenting dendritic cell subsets in the skin-draining lymph node. Proc Natl Acad Sci USA 113: 1044–1049.  doi: 10.1073/pnas.1513607113
    [163] 164. Wan YY, Flavell RA (2009) How diverse-CD4 effector T cells and their functions. J Mol Cell Biol 1: 20–36.  doi: 10.1093/jmcb/mjp001
    [164] 165. Lanzavecchia A (1985) Antigen-specific interaction between T and B cells. Nature 314: 537–539.  doi: 10.1038/314537a0
    [165] 166. Shumilina E, Huber SM, Lang F (2011) Ca2+ signaling in the regulation of dendritic cell functions. Am J Physiol Cell Ph 300: C1205–C1214.  doi: 10.1152/ajpcell.00039.2011
    [166] 167. Cowen DS, Lazarus HM, Shurin SB, et al. (1989) Extracellular adenosine triphosphate activates calcium mobilization in human phagocytic leukocytes and neutrophil/monocyte progenitor cells. J Clin Invest 83: 1651–.  doi: 10.1172/JCI114064
    [167] 168. Bretou M, Sáez PJ, Sanséau D, et al. (2017) Lysosome signaling controls the migration of dendritic cells. Sci Immunol 2: In press.
    [168] 169. Vukcevic M, Zorzato F, Spagnoli G, et al. (2010) Frequent calcium oscillations lead to NFAT activation in human immature dendritic cells. J Biol Chem 285: 16003–16011.  doi: 10.1074/jbc.M109.066704
    [169] 170. Jégouzo SAF, Quintero-Martinez, Ouyang X, et al. (2013) Organization of the extracellular portion of the macrophage galactose receptor: a trimeric cluster of simple binding sites for N-acetylgalactosamine. Glycobiology 23: 853–864.  doi: 10.1093/glycob/cwt022
    [170] 171. Humeau J, Bravo-San PJ, Vitale I, et al. (2017) Calcium signaling and cell cycle: progression or death. Cell Calcium 17: In press. 
    [171] 172. Nicotera P, Orrenius S (1998) The role of calcium in apoptosis. Cell Calcium 23: 173–180.  doi: 10.1016/S0143-4160(98)90116-6
    [172] 173. Schwarz EC, Qu B, Hoth M (013) Calcium, cancer and killing: the role of calcium in killing cancer cells by cytotoxic T lymphocytes and natural killing cells. BBA-Mol Cell Res 1833: 1603–1611. 
    [173] 174. Cui C, Merritt R, Fu L, et al. (2017) Targeting calcium signaling in cancer therapy. Acta Pharm Sinica B 7: 3–17.  doi: 10.1016/j.apsb.2016.11.001
    [174] 175. Halling DB, Liebeskind BJ, Hall AW, et al. (2016) Conserved properties of individual Ca2+-binding sites in calmodulin. Proc Nat Acad Sci USA 113: E1216–E1225.  doi: 10.1073/pnas.1600385113
    [175] 176. Agrawal RS, Connolly SF, Herrmann TL, et al. (2007) MHC class II levels and intracellular localization in human dendritic cells are regulated by calmodulin kinase II. J Leukocyte Biol 82: 686–699.  doi: 10.1189/jlb.0107045
    [176] 177. Connolly SF, Kusner DJ (2007) The regulation of dendritic cell function by calcium-signaling and its inhibition by microbial pathogens. Immunol Res 39: 115–127.  doi: 10.1007/s12026-007-0076-1
    [177] 178. Shi Y (2009) Serine/threonine phosphatases: mechanism through structure. Cell 139: 468–484.  doi: 10.1016/j.cell.2009.10.006
    [178] 179. Song MS, Salmena L, Pandolfi PP (2012) The functions and regulation of the PTEN tumor suppressor. Nat Rev Mol Cell Bio 13: 283–296. 
    [179] 180. Cho US, Xu W (2007) Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. Nature 445: 53–57.  doi: 10.1038/nature05351
    [180] 181. Feske S (2007) Calcium signaling in lymphocyte activation and disease. Nat Rev Immunol 7: 690–702.  doi: 10.1038/nri2152
    [181] 182. Müller MR, Rao A (2010) NFAT, immunity and cancer: a transcription factor comes of age. Nat Rev Immunol 10: 645–656.  doi: 10.1038/nri2818
    [182] 183. Nakanishi A, Hatano N, Fujiwara Y, et al. (2017) AMP-activated protein-kinase-mediated feedback phosphorylation controls the Ca2+/calmodulin dependence of Ca2+/CaM-dependent protein kinase kinase β. J Biol Chem 292: 19804–19813.  doi: 10.1074/jbc.M117.805085
    [183] 184. Gaertner TR, Kolodziej SJ, Wang D, et al. (2004) Comparative analysis of the three-dimensional structures and enzymatic properties of α, β, γ, and δ isoforms of Ca2+-calmodulin-dependent protein kinase II. J Biol Chem 279: 12484–12494.  doi: 10.1074/jbc.M313597200
    [184] 185. Wiede F, Dudakov JA, Lu KH, et al. (2017) PTPN2 regulates T cell lineage commitment and αβ versus γδ specification. J Exp Med 214: 2733–2758.  doi: 10.1084/jem.20161903
    [185] 186. Wang X, Marks CR, Perfitt TL, et al. (2017) A novel mechanism for Ca2+/calmodulin-dependent protein kinase II targeting to L-type Ca2+ channels that initiates long-range signaling to the nucleus. J Biol Chem 292: 17324–17336.  doi: 10.1074/jbc.M117.788331
    [186] 187. Lin MY, Zal T, Ch'En IL, et al. (2005) A pivotal role for the multifunctional calcium/calmodulin-dependent protein kinase II in T cells: from activation to unresponsiveness. J Immunol 174: 5583–5592.  doi: 10.4049/jimmunol.174.9.5583
    [187] 188. Ratner AJ, Bryan R, Weber A, et al. (2017) Cystic fibrosis pathogens activate Ca2+-dependent mitogen-activated protein kinase signaling pathways in airway epithelial cells. J Biol Chem 276: 19267–19275. 
    [188] 189. Bononi A, Agnoletto C, De ME, et al. (2011) Protein kinases and phosphatases in the control of cell fate. Enz Res 2011: 329098–329113. 
    [189] 190. Suzuki K, Hata S, Kawabata Y, et al. (2004) Structure, activation, and biology of calpain. Diabetes 53: S12–S18.  doi: 10.2337/diabetes.53.2007.S12
    [190] 191. Frangioni JV, Oda A, Smith M, et al. (1993) Calpain-catalyzed cleavage and subcellular relocation of protein phosphotyrosine phosphatase 1B (PTP-1B) in human platelets. EMBO J 12: 4843–4856. 
    [191] 192. Baba Y, Kurosaki T (2016) Role of calcium signaling in B cell activation and biology. Curr Top Microbiol 393: 143–147. 
    [192] 193. Vaeth M, Zee I, Concepcion AR, et al. (2015) Ca2+ signaling but not store-operated Ca2+ entry is required for the function of macrophages and dendritic cells. J Immunol 195: 1202–1217.  doi: 10.4049/jimmunol.1403013
    [193] 194. Ledderose C, Bao Y, Lidicky M, et al. (2014) Mitochondria are gate-keepers of T cell function by producing the ATP that drives purinergic signaling. J Biol Chem 289: 25936–25945.  doi: 10.1074/jbc.M114.575308
    [194] 195. Zizzari IG, Napoletano C, Battisti F, et al. (2015) MGL receptor and immunity: when the ligand can make the difference. J Immunol Res 2015: 450695–450702. 
    [195] 196. van Vliet SJ, Bay S, Vuist IM, et al. (2013) MGL signaling augments TLR2-mediated responses for enhanced IL-10 and TNF-α secretion. J Leukocyte Biol 94: 315–323.  doi: 10.1189/jlb.1012520
    [196] 197. Nunes P, Demaurex N (2010) The role of calcium signaling in phagocytosis. J Leukocyte Biol 88: 57–68.  doi: 10.1189/jlb.0110028
    [197] 198. Lm VDB, Gringhuis SI, Geijtenbeek TB (2012) An evolutionary perspective on C-type lectins in infection and immunity. Ann Ny Acad Sci 1253: 149–158.  doi: 10.1111/j.1749-6632.2011.06392.x
    [198] 199. Kushchayev SV, Sankar T, Eggink LL, et al. (2012) Monocyte galactose/N-acetylgalactosamine-specific C-type lectin receptor stimulant immunotherapy of an experimental glioma. Part 1: stimulatory effects on blood monocytes and monocyte-derived cells of the brain. Cancer Manag Res 4: 309–323.
    [199] 200. Kushchayev SV, Sankar T, Eggink LL, et al. (2012) Monocyte galactose/N-acetylgalactosamine-specific C-type lectin receptor stimulant immunotherapy of an experimental glioma. Part II: combination with external radiation improves survival. Cancer Manag Res 4: 325–334. 
    [200] 201. Roby KF, Eggink LL, Hoober JK (2017) An innovative immunotherapeutic strategy for ovarian cancer: glycomimetic peptides [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017, Washington DC. Available from: http://cancerres.aacrjournals.org/content/77/13_Supplement/170.
  • This article has been cited by:

    1. Tareq Eriqat, Moa’ath N. Oqielat, Rania Saadeh, Ahmad El-Ajou, Ahmad Qazza, Mohammed Abu Saleem, Optimized technique and dynamical behaviors of fractional Lax and Caudrey–Dodd–Gibbon models modelized by the Caputo fractional derivative, 2024, 10, 26668181, 100737, 10.1016/j.padiff.2024.100737
    2. R. Venkatesan, C. Kumar, C. R. Balamurugan, Tomonobu Senjyu, Enhancing power quality in grid-connected hybrid renewable energy systems using UPQC and optimized O-FOPID, 2024, 12, 2296-598X, 10.3389/fenrg.2024.1425412
  • Reader Comments
  • © 2017 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(9101) PDF downloads(1207) Cited by(8)

Figures and Tables

Figures(3)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog